REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Preparations Characterized By Special Physical Form > Tablets, Lozenges, Or Pills Tablets, Lozenges, Or PillsTablets, Lozenges, Or Pills patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178154 - Calcium carbonate granulation Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet ... 08/02/07 - 20070178153 - Calcium carbonate granulation Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet ... 08/02/07 - 20070178152 - Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents Disclosed herein are pharmaceutical compositions comprising carboxyalkylcellulose esters for delivery of pharmaceutically active substances having low solubility in a medium such as water, an acidic aqueous buffer, a neutral aqueous buffer, or a basic aqueous buffer. Also disclosed are methods for making pharmaceutical compositions and methods of administering the compositions. ... 08/02/07 - 20070178151 - Spray dried pharmaceutical compositions The present invention relates to novel compositions containing the NK3 receptor antagonist talnetant which compositions have enhanced bioavailability. In addition, the invention relates to processes for the preparation and to uses of the compositions in therapy. ... 08/02/07 - 20070178150 - Pharmaceutical compositions A pharmaceutical composition in the form of a chewable tablet for the suppression of gastric reflux comprising an alginic acid or salt thereof, a water-soluble carbonate radical precursor, a calcium salt, a first bulk sweetener, and a binding agent. The calcium salt and either or both of the bulk sweetener ... 07/26/07 - 20070172524 - Process for preparing a solid pharmaceutical composition The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof which avoids a wet granulation step and results in very stable pharmaceutical compositions, like tablets. ... 07/19/07 - 20070166376 - Solid pharmaceutical preparation The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which shows in vivo dissolution behavior of an insulin sensitizer, which is similar to the dissolution behavior of an insulin sensitizer from “a solid preparation containing an insulin sensitizer alone as an ... 07/12/07 - 20070160666 - Pharmaceutical formulation The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability. ... 07/12/07 - 20070160665 - Chlorthalidone combinations The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension. ... 07/05/07 - 20070154545 - Dry formulations of aripiprazole The invention encompasses dry compression pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the dry compression pharmaceutical composition. ... 07/05/07 - 20070154544 - Wet formulations of aripiprazole The invention encompasses wet granulation pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the wet granulation pharmaceutical composition. ... 07/05/07 - 20070154543 - Solid preparation for oral use Upon performing the clinical study of (S)-2-[3-[N-[4-(4-fluorophenoxy)benzyl]carbamoyl]-4-methoxybenz yl]butanoic acid (hereinafter abbreviated as KRP-101), of which improvement in the lipidmetabolism is expected in a microdose, no oral solid dosage form that allows KRP-101 to be administered quantitatively has been embodied. After mixing KRP-101 with additives (excipient, disintegrator and lubricant), the mixture ... 06/28/07 - 20070148236 - Pharmaceutical compositions of adsorbates of amorphous drug Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer. ... 06/28/07 - 20070148235 - Pharmaceutical composition The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a pharmaceutical product for oral administration, comprising the granular composition. The product excellently masks a disagreeable taste possessed by a drug ... 06/28/07 - 20070148234 - Pharmaceutical formulations The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. ... 06/28/07 - 20070148233 - Pharmaceutical formulations of fenofibrate having improved bioavailability Provided are pharmaceutical compositions of fenofibrate, and dosage forms containing them, that include fenofibrate, a polyethylene glycol, and a polyethylene-polypropylene glycol; wherein the compositions are made by subliming a sublimable carrier from a combination of fenofibrate, the polyethylene glycol, and the polyethylene-polypropylene glycol with the sublimable carrier, for example menthol. ... 06/28/07 - 20070148232 - Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers Solid compositions with improved physical stability comprise an amorphous, low-solubility drug, a poloxamer, and a stabilizing polymer. The compositions provide good physical stability during storage and concentration enhancement of dissolved drug when administered to an aqueous environment of use. ... 06/28/07 - 20070148231 - Fast-disintegrating tablets The invention relates to a method of manufacture of fast-disintegrating tablets, and tablets obtained comprising chemicals, foodstuff, oral drug components and the like. The method is characterized in that the components in pulverized form are contacted with a pressurized liquefied gas or gas mixture, homogenized, introduced into moulds under pressure, ... 06/28/07 - 20070148230 - Medicament-containing particle and a solid preparation containing the particle The invention provides a medicament-containing particle wherein an unpleasant taste of the medicament is alleviated, which is obtainable by mixing and granulating the following ingredients: (1) the medicament with an unpleasant taste, (2) methylcellulose and (3) mannitol; and a solid preparation including the particle. The invention can make an unpleasant ... 06/28/07 - 20070148229 - Tablet with coloured core Press-coated tablets comprising a care and a coating. The core contains an active substance and a colouring agent such that when the tablet is exposed to penetrating radiation the core is contrasted with the coating and is visible through the coating. The invention also relates to the use' of a ... 06/21/07 - 20070141145 - Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting ... 06/21/07 - 20070141144 - Oral delivery system The present invention relates generally to formulations comprising paracetamol. More particularly, the present invention provides a swallow formulation comprising paracetamol which facilitates the rapid delivery of paracetamol into the circulatory system following oral administration. The present invention further relates to methods for inducing efficient pain relief including an analgesic effect ... 06/21/07 - 20070141143 - Solid compositions of low-solubility drugs and poloxamers Solid compositions of low-solubility drugs and poloxamers that provide concentration enhancement when administered to an aqueous environment of use are disclosed. ... 06/21/07 - 20070141142 - Pseudo-thermosetting neutralized chitosan composition forming a hydrogel and a process for producing the same The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with an hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller ... 06/21/07 - 20070141141 - Pharmaceutical composition An immediate release pharmaceutical composition comprising 4-(3′-chloro-4′-fluoroanilino)-7-methoxy-6-(3-mor-pholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof (the Agent); a water-soluble acid; and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The claimed compositions inhibit the rate of precipitation of the Agent from solution and/or provide enhanced solubilisation of the agent ... 06/21/07 - 20070141140 - Semi-solid formulations for immediate release intended for the oral administration of drugs The present invention relates to a pharmaceutical composition suitable for oral administration, in the form of semisolid matrix, comprising an active ingredient poorly soluble in water and present in a quantity of from 15 to 45% by weight of the percent composition of the pharmaceutical composition; a surfactant agent constituted ... 06/14/07 - 20070134325 - Beta-lactam antibiotic-containing tablet and production thereof This invention provides β-lactam antibiotic-containing tablets capable of being orally taken either as such owing to their being small-sized, hence still easily swallowable, or, in the case of administration to the aged encountering some difficulty in swallowing, in the form of dispersions resulting from easy self-disintegration upon being dropped into ... 06/14/07 - 20070134324 - Therapeutic combinations The goal of the present invention is a pharmaceutical composition including a betaine and an anti-cholesterol agent. The association and co-administration of at least a betaine allows to reducing side effects related to anti-cholesterol agents administration, in particular their deleterious effects on liver, pancreas and kidneys. ... 06/14/07 - 20070134323 - Ziprasidone suspension Compositions comprising ziprasidone free base or a difficult to wet pharmaceutically acceptable ziprasidone acid addition salt, a polysorbate, and colloidal silicon dioxide form good aqueous suspensions having a useful shelf life and are easily re-suspended if settling occurs. ... 06/14/07 - 20070134322 - Modified and pulsatile release pharmaceutical formulations of escitalopram The present invention relates to modified and pulsatile release pharmaceutical formulations of escitalopram and their use for the treatment of central nervous system disorders, including mood disorders (e.g., major depressive disorder) and anxiety disorders (e.g., generalized anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder, including panic ... 06/14/07 - 20070134321 - Pharmaceutical tablets with height greater than width Described is a compressed multiple layer pharmaceutical tablet that has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been ... 06/14/07 - 20070134320 - Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions A composition and treatment regimen for the amelioration of epidermal herpetic lesions caused by Herpes Simplex Virus (HSV-1) symptoms, Herpes Zoster, and Herpes Genitalia. The treatment includes a regimen of oral administration of a composition including from about 15 to 50 mg of zinc sulfate, from about 5 to 20 ... 06/14/07 - 20070134319 - Pharmaceutical formulations of bisphosphonates A pharmaceutical formulation comprising an oral dosage form containing a bisphosphonic acid or a salt thereof and an inactive ingredient selected from: an ester of a medium chain fatty acid, or a lipophilic polyethylene glycol ester, said inactive ingredient having a hydrophilic lipophilic balance (HLB) of from about 1 to ... 06/14/07 - 20070134318 - Non-tabletted, chewable, individually dosed administration forms Non-tabletted, individually dosed administration forms comprising a composition of at least one pharmaceutically active substance dissolved or dispersed within a matrix material comprising a mixture of at least 0.2% by weight of a gelatine, at least one stabilising agent and at least one water-soluble alcohol and/or water as a solvent, ... 06/14/07 - 20070134317 - Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate A non effervescent tablet of sodium naproxen, comprising a tablet core and, if desired, a sugar or film coat, wherein the tablet core, based on the weight of the tablet core, consists of 30 to 99% by weight sodium naproxen and 70 to 1% by weight auxiliary agent component comprising ... 06/07/07 - 20070128274 - Direct coating solid dosage forms using powdered materials The present invention provides a method and apparatus for dry coating solid dosage forms. The method includes the steps of placing solid dosage forms in a rotatable, electrically grounded housing, and spraying a film forming polymer powder composition into the housing during rotation thereof to form a polymer coating on ... 06/07/07 - 20070128273 - Composition containing medicine extremely slightly soluble in water and method for preparation thereof A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter ... 05/31/07 - 20070122476 - Storage stable thyroxine active drug formulations and methods for their production This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, ... 05/31/07 - 20070122475 - Taste masking composition A composition for delivery of a medicament that has a bitter taste and/or causes throat catch is provided. The composition contains Carbomer 934, Carbomer 971, Carbomer 974, PEG-5M or a mixture thereof in an amount sufficient to mask the bitter taste of the medicament and/or throat catch. ... 05/31/07 - 20070122474 - Pharmaceutical preparation comprising an active dispersed on a matrix The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix ... 05/31/07 - 20070122473 - Aminosugar and/or glycosaminoglycan composition having therapeutic use An embodiment of the invention provides a composition having one or more active ingredients such as an aminosugar, more particularly, glucosamine, glucosamine salt, and mixtures thereof, and a glycosaminoglycan, more particularly, chondroitin, chondroitin salts, and mixtures thereof having a therapeutic use and is stable for at least 24 months. Additionally, ... 05/31/07 - 20070122472 - Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability Tablets of a pharmaceutical, nutritional or vitamin active compound or composition, e.g. a poorly compressible drug are made by direct compression using a synergistic binder composition of co-processed (a) copolymer of vinylpyrrolidone (VP) and vinyl acetate (VA) and (b) microcrystalline cellulose (MCC), in a wt. ratio of (a):(b) of 1-30:99-70, ... 05/31/07 - 20070122471 - Method of improving suitability for granulation The present invention provides a granulated product having improved granulatability which contains a compound with poor wettability and a surfactant, particularly the granulated product wherein at least about 35% by weight with respect to the total weight of the product does not pass through a 100-mesh sieve, and a method ... 05/24/07 - 20070116762 - Compositions of stabilized ramipril in combination with another active agent A pharmaceutical composition comprising ramipril, another active agent, and a blending agent, wherein in the ramipril is coated by the blending agent, and wherein the blending agent is glyceryl behenate, glyceryl stearate, stearyl alcohol, macrogol stearate ether, palmitosearate, ethylene glycol, polyethylene glycol, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer ... 05/24/07 - 20070116761 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts ... 05/24/07 - 20070116760 - Pharmaceutical compositions comprising meloxicam and methods of their preparation The present invention encompasses a method of evaluating pharmaceutical compositions of meloxicam whereby one can correlate in vitro properties to in vivo properties, and pharmaceutical compositions developed using the method. ... 05/24/07 - 20070116759 - Pharmaceutical compositions of telmisartan The present invention provides a pharmaceutical composition of telmisartan comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent wherein the composition comprises less than 25% of water soluble diluents. The telmisartan compound is preferably present from about 12.5% to about 15.5%. ... 05/24/07 - 20070116758 - Atorvastatin formulation Provided are atorvastatin compositions which reduce the effect of food on the bioavailability of atorvastatin and methods for making such compositions. Also provided are methods of reducing low density lipoprotein by administering the compositions of the invention. ... 05/17/07 - 20070110802 - Wet granulation process The present invention relates to a process of wet granulation, and specifically wet granulation of material that is susceptible to convert from anhydrous form to hydrate form. ... 05/17/07 - 20070110801 - Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method The object of the invention is a process for diffusion of lipophilic molecules in an aqueous medium, in particular derivatives of the aryl-carboxylic family for the treatment of buccopharyngeal ailments, molecules with anti-inflammatory, anti-mycotic, central action analgesic or anti-allergic activity, characterized in that it consists in resorting to salts of ... 05/10/07 - 20070104784 - Compositions and methods of treatment comprising amoxicillin and potassium clavulante with xanthan Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet. ... 05/10/07 - 20070104783 - Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders Bioadhesive sticker tablets which are applied directly to vaginal, rectal and/or oral mucosa are described herein. In one embodiment, the sticker tablets are applied directly to ulcers or lesions in the oral cavity. The compositions adhere immediately upon administration, swell over time, and remain adherent to the ulcer or lesion ... 05/10/07 - 20070104782 - Modified release tablet formulations with enhanced mechanical properties A method of formulating a drug in solid dosage form of a specified hardness, the drug containing at least one pharmaceutically active agent that has a pH dependent release profile, at least one non-pH dependent sustained release agent, and an effective amount of Eudragit L100-55. ... 05/03/07 - 20070098789 - Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same Organoleptically acceptable solid oral dosage formulations of ibuprofen, and methods of making and using the same, are provided. A feature of the subject formulations is that they include ibuprofen and a masking component. In certain embodiments, the masking component includes one or more of a cooling agent, an organic acid ... 05/03/07 - 20070098788 - Non-benzodiazepine hypnotic compositions Pharmaceutical compositions comprising non-benzodiazepine hypnotic drugs or their pharmaceutically acceptable salts, solvates, enantiomers or mixtures and processes for preparing the same. The invention also includes immediate release and extended release pharmaceutical compositions comprising non-benzodiazepine hypnotic drugs, useful for sleep induction and sleep maintenance. ... 05/03/07 - 20070098787 - Composition for preventing and treating varicose veins of lower extremities A preventive/therapeutic agent for varicose veins or a composition for the prevention or alleviation of symptoms relevant to varicose veins. The preventive/therapeutic agent for varicose veins or the composition for the prevention or alleviation of symptoms relevant to varicose veins each is characterized by containing eicosapentaenoic acid. ... 04/26/07 - 20070092564 - Orally distintegrating formulation and process for preparing the same An orally disintegrating formulation and its preparation are provided. The orally disintegrating formulation comprises an effective amount of a pharmaceutically active ingredient and a matrix, wherein the matrix contains an amino acid and pullulan. The orally disintegrating formulation can disintegrate rapidly in oral cavity and be taken without aid of ... 04/26/07 - 20070092563 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts ... 04/26/07 - 20070092562 - Product and process for increasing compactibility of carbohydrates The present invention includes a method for preparing a highly compactible carbohydrate product, and the product itself. In one embodiment, a composition according to the present invention is a quick-dissolving composition that includes polyols. ... 04/26/07 - 20070092561 - Water-soluble aspirin composition Compositions in which aspirin is present in combination with alkaline compounds, especially those containing water of crystallization (hydrates), deteriorate on standing. This deterioration may take several forms: It can be a physical deterioration in which such aspirin compositions become completely unmanageable, wet, gummy, sticky masses; or chemical decomposition in which ... 04/19/07 - 20070087051 - Pharmaceutical composition A method of treating a cyclooxygenase-2 dependent disorder or condition comprising administering a solid formulation of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid which has a residual moisture within predetermined levels. ... 04/19/07 - 20070087050 - Orally disintegratable simvastatin tablets An orally disintegratable tablet containing simvastatin and silicified microcrystalline cellulose is provided with a non-alkaline lubricant. ... 04/12/07 - 20070082048 - Sleep aid formulations Orally dissolvable dosage forms comprising sleep aids such as benodiazepines are described. The dosage forms may be in the form of tablets or strips. In certain embodiments, the dosage forms may comprise particles, granules, microgranules, or crystals, and a matrix. The particles, granules or microgranules comprise a combination of immediate-release ... 04/12/07 - 20070082047 - Solid preparation A chewable tablet comprising a group which contains an acid-labile active ingredient and at least one basic substance selected from alkaline earth metal carbonate, metal oxide and metal hydroxide, and a group which does not contain an acid-labile active ingredient and contains at least one ingredient selected from alkaline earth ... 04/05/07 - 20070077297 - Modified release ibuprofen dosage form The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 ... 04/05/07 - 20070077296 - Pharmaceutical preparation containing meloxicam The invention relates to novel solid formulations comprising as pharmaceutically active compound meloxicam and to processes for producing such solid formulations. The invention furthermore relates to a method for manufacturing a medicament for the prevention and/or treatment of pain, inflammation, fever, acute mastitis, diarrhoea, locomotive disorders, lameness, osteoarthritis, problems of ... 04/05/07 - 20070077295 - Method and composition for pharmaceutical product This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF. ... 03/29/07 - 20070071815 - Oral formulation of creatine derivatives and method of manufacturing same Oral formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt ... 03/29/07 - 20070071814 - Vaginal tablets comprising misoprostol and methods of making and using the same The present invention is directed to vaginal tablets comprising misoprostol and a pharmaceutically acceptable pH insensitive, hydrophilic cellulose material, wherein the vaginal tablets do not contain a hydrophobic release controlling agent, and wherein the misoprostol and the pharmaceutically acceptable pH insensitive, hydrophilic cellulose material are in a ratio of about ... 03/29/07 - 20070071813 - Novel dosage formulation wherein the definitions are described in claim 1, or pharmaceutically acceptable acid addition salts thereof and a water soluble poloxamer in which the compound of formula I and the water soluble poloxamer are processed by hot melt extrusion, and then the hot melt extrudate is mixed with other ingredients to ... 03/29/07 - 20070071812 - Pharmaceutical composition containing fenofibrate and method for the preparation thereof The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables ... 03/29/07 - 20070071811 - Stable combinations of amlodipine besylate and benazepril hydrochloride The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same. ... 03/29/07 - 20070071810 - Additive for tablets A disintegrant for tablets consisting of an α-1,4-glucan having a degree of polymerization of not less than 180 and less than 1230 and a dispersity (weight average molecular weight “Mw”/number average molecular weight “Mn”) of not more than 1.25 or a modified product thereof. A binder for tablets consisting of ... 03/22/07 - 20070065509 - Method of preparing sustained-release preparations of quinolone antibiotics The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay. ... 03/22/07 - 20070065508 - Composition comprising vitamin b12 and acid reducing agent and uses thereof The present invention provides compositions and methods for treating or reducing the risk of a vitamin B12 deficiency in a subject having or in need of a gastrointestinal acid reduction treatment. ... 03/22/07 - 20070065507 - Bisphosphonate formulation A bisphosphonate for treatment of osteoporosis is formulated with an amount of an antifoaming agent effective for reducing foaming in the stomach, leading to reduced reflux and oesophageal irritation in use and increased patient compliance. ... 03/22/07 - 20070065506 - Keratin and soluble derivatives thereof for a nutraceutical and to reduce oxidative stress and to reduce inflammation and to promote skin health Keratin and derivatives thereof, preferably S-sulfonated keratin intermediate filament protein, S-sulfonated keratin high sulfur protein, and S-sulfonated peptides provide antioxidant activity, e.g., that equal to 200-2200 μmol TEAC/100 g or 100 ml, and are useful in an oral supplement to cause reduction in oxidative stress and benefits stemming therefrom, e.g., ... 03/22/07 - 20070065505 - Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the ... 03/15/07 - 20070059361 - Fast-disintegrating epinephrine tablets for buccal or sublingual administration Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations similar to those achieved by an approximately 0.3 mg epinephrine dose in the thigh (Epi-Pen). ... 03/15/07 - 20070059360 - Water-dispersible anti-retroviral pharmaceutical compositions Provided herein are water-dispersible pharmaceutical compositions comprising a combination of one or more anti-retroviral drugs useful for the treatment of Human Immunodeficiency Virus (HIV) infections. Also provided are processes for preparing such water-dispersible pharmaceutical compositions. ... 03/15/07 - 20070059359 - Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof The invention relates to immediate-release and high-drug-load solid pharmaceutical formulations comprising non-micronized (4-chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl] as well as pharmaceutically acceptable salts thereof. ... 03/15/07 - 20070059358 - Matrix adjuvants and the drop pills prepared with them The present invention relates to the matrix adjuvants for drop pills and the preparation of the drop pills. The matrix adjuvants for drop pills of the present invention comprise new matrix adjuvants with or without the plastifying components, which are typically natural matrix adjuvants derived from plants and of safety ... 03/15/07 - 20070059357 - Adiponectin production enhancer The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor. ... 03/15/07 - 20070059356 - Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, ... 03/08/07 - 20070053978 - Process for co-spray drying liquid herbal extracts with dry silicified mcc A process for preparing dry extracts from a liquid extract and at least one additional substance by a spray-drying process, characterized in that said at least one additional substance is added to the spray-drying process in a dry form during the spray-drying processes. ... 03/08/07 - 20070053977 - Calcium carbonate granulation Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet ... 03/08/07 - 20070053976 - Novel combination of drugs as antidepressant A novel antidepressant composition of a cholinesterase inhibitor in combination with a selective serotonin reuptake inhibitor, milnacipran or duloxetine is disclosed, which has a significantly high therapeutic effect as compared with conventional antidepressants. The therapeutic method using a cholinesterase inhibitor in combination with a selective serotonin reuptake inhibitor, milnacipran or ... 03/08/07 - 20070053975 - Ramipril formulation A Ramipril formulation rapidly disintegrates after ingestion and exhibits substantially no food effect. ... 03/08/07 - 20070053974 - Stable oral composition The present invention provides a stable oral composition comprising a therapeutically effective amount of desloratadine and a stabilizer selected from the group comprising an antioxidant, a pharmaceutically acceptable organic compound that provides an alkaline pH, an alkali metal salt, or mixtures thereof, and pharmaceutically acceptable excipients. ... 03/08/07 - 20070053973 - Amorphous antibiotic composition comprising cefditoren pivoxil According to the present invention, there is provided a solid dispersion composition which can maintain amorphous cefditoren pivoxil in a suspension for a long period of time. The present invention is a solid dispersion composition comprising at least 0.1 mg of a sugar ester fatty acid on the basis of ... 03/01/07 - 20070048374 - Bazedoxifene acetate formulations The present invention is directed to formulations of bazedoxifene acetate that have reduced polymorph conversion, compositions containing the same, preparations thereof, and uses thereof. ... 03/01/07 - 20070048373 - Dried milled granulate and methods The present invention relates to a method of producing a dried wet granulate having a desirable average particle size and particle size distribution and dosage forms made from that granulate. ... 03/01/07 - 20070048372 - Method for treating non-inflammatory osteoarthritic pain A method for treating non-inflammatory osteoarthritic pain in a subject comprises administering to the subject a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof. ... 03/01/07 - 20070048371 - Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily Therapeutic formulations of guanfacine in a once a day single dose form which have useful overall tablet sizes are disclosed. ... 03/01/07 - 20070048370 - Pharmaceutical formulation for salts of monobasic acids with clopidogrel A pharmaceutical formulation in the form of a tablet which contains, as active substance, a salt of a monobasic acid with clopidogrel is disclosed herein. ... 03/01/07 - 20070048369 - Mucosal delivery tablet Mucoadhesive tablets have a convex surface, a diameter to cup depth ratio of 4-20 and a cup depth to edge thickness ratio of greater than 0.75 swiftly adheres and conforms to the contacting tissue. The tablets are used to administer actives such as, for example, benzocaine. ... 02/22/07 - 20070042039 - Calcium carbonate granulation Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet ... 02/22/07 - 20070042038 - Progestin co-micronized with a surfactant, pharmaceutical composition comprising same, methods for making same and uses thereof The invention concerns a progestin co-micronized with a surfactant and a pharmaceutical composition comprising said gestagenic. The invention also concerns methods for preparing same. ... 02/15/07 - 20070036854 - Therapeutic applications of pro-apoptotic benzodiazepines wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune ... 02/15/07 - 20070036853 - Generally linear effervescent oral fentanyl dosage form and methods of administering Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa. ... 02/15/07 - 20070036852 - Rapidly dispersing/disintegrating compositions The present invention relates to a rapidly dispersing/disintegrating, taste masked oral ondansetron dosage forms and a simple and economic process for their manufacture which can be easily scaled up. In particular, the present invention relates to a compressed dosage form for oral administration capable of being rapidly disintegrated comprising a ... 02/15/07 - 20070036851 - Acid labile drug compositions A composition and method of making a pharmaceutical dosage form containing an acid labile drug bound to an ion exchange resin is provided. The composition may be coated with a low acid content enteric coating. The binding of the acid labile drug to the exchange resin stabilizes the drug against ... 02/08/07 - 20070031489 - Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness The present invention relates to methods for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed with respiratory illness by administering an analgesic composition comprising a sub-analgesic dosage of a p-opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and ... 02/08/07 - 20070031488 - Method of administering a partial dose of a segmented pharmaceutical tablet A drug-containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug. ... 02/01/07 - 20070026064 - Pharmaceutical dosage forms having watermark-type identification and authentication inditia Oral solid dosage forms having holographic markings or identification marks such as a watermark thereon and methods of preparing the same are disclosed. One preferred method of applying an identification mark on a pharmaceutical dosage form described herein includes applying a film coating having a first color to an oral ... 02/01/07 - 20070026063 - Composition for coating comprising low-substituted cellulose ether and coated preparation having unpleasant taste masked The present invention is a composition for coating comprising a wet-milled product obtained by suspending low-substituted cellulose ether having a molar substitution of from 0.05 to 1.0 per anhydrous glucose unit in water and then applying a shear force to the aqueous dispersion. The present invention is also a coated ... 01/25/07 - 20070020332 - Tannate compositions, methods of making and methods of use Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions. ... 01/25/07 - 20070020331 - Coated tablet with zero-order of near zero-order release kinetics Tablets for the controlled release of an active ingredient in a zero-order or near zero-order fashion are provided. The tablet includes a core and a coating. The core includes at least one active pharmaceutical agent and a polyethylene oxide with a molecular weight of between about 1,000,000 and 10,000,000, preferably ... 01/25/07 - 20070020330 - Compositions comprising azelastine and methods of use thereof The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize ... 01/25/07 - 20070020329 - Methods of formulating linezolid A method of formulating linezolid to provide a pharmaceutical composition comprising linezolid wherein the linezolid is linezolid Form IV substantially free of linezolid Form II, a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II and povidone, methods of treating a condition responsive to linezolid in ... 01/18/07 - 20070014857 - Pharmaceutical formulation having a masked taste and method for the production thereof The invention relates to a pharmaceutical formulation in the form of a powder which is administered orally in an aqueous suspension, having a masked taste, and comprising at least one cellulose polymer, a methacrylic polymer and an active ingredient which is distributed in a homogeneous manner in a molecular state ... 01/18/07 - 20070014856 - Rapidly disintegrable pharmaceutical composition The present invention relates to a pharmaceutical composition useful for rapid disintegration, which comprises a sparingly soluble medicament held on a gel-forming water-soluble polymer as a solid dispersion, wherein it contains a salt substance that comprises an alkali and a weak or strong acid and has an endothermic standard enthalpy ... 01/18/07 - 20070014855 - Stable desloratadine compositions Stable pharmaceutical compositions of desloratadine or pharmaceutically acceptable salts in combination with one or more therapeutically active compounds. ... 01/18/07 - 20070014854 - Novel granulation process One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable ... 01/18/07 - 20070014853 - Pharmaceutical dosage form containing novel pharmaceutical granulate One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable ... 01/18/07 - 20070014852 - Tablets having a printed separation mark to guide breaking The invention provides a novel “separation marking” on a tablet as a means for assisting in the identification of a region on the tablet that is desired to be able to be broken from time to time. Said breaking allows production of smaller dosage forms known herein as tablettes. In ... 01/18/07 - 20070014851 - Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts In a solid pharmaceutical preparation containing water-soluble salts of levothyroxine and/or liothyronine as active ingredients, the water activity of said pharmaceutical preparation is adjusted to values of below 0.4 and, preferably, 0.1 to 0.3, measured at room temperature. ... 01/18/07 - 20070014850 - Process for the preparation of dispersible tablets of cephalexin The present invention relates to dispersible tablets of cephalexin and a process for their preparation. ... 01/11/07 - 20070009595 - Sugar alcohol composition for tableting A powdery sugar alcohol composition which is useful as a tableting excipient is provided. The composition of the invention consists essentially of a crystalline sugar alcohol and an amorphous sugar alcohol, provided that the composition comprises 2-12 wt % of amorphous sorbitol. By employing the sugar alcohol composition as tableting ... 01/11/07 - 20070009594 - Compositions and methods for treatment of cycle-related symptoms Methods are provided for treating cycle-related symptoms through administration of at least one progestin and at least one estrogen to a female subject. ... 01/11/07 - 20070009593 - Methods of treating cancer Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a ... 01/11/07 - 20070009592 - Immediate release pharmaceutical granule compositions and a continuous process for making them An immediate or fast release pharmaceutical granule composition comprising at least one drug (i) classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein the said drug constitutes at least about 0.5% by weight and no more than 50% by weight of the composition, and further comprising ... 01/11/07 - 20070009591 - Ace inhibitor formulation A process for preparing pharmaceutical micro-tablets comprises (a) preparing a tableting mix that comprises an ACE inhibitor, for example moexipril hydrochloride, and excipient ingredients that comprise one or more lubricants; and (b) compressing the tableting mix in a tablet press, to form micro-tablets having an average uncoated weight of about ... 01/11/07 - 20070009590 - Physiologically active composition based on phosphatidylserine This physiologically active composition contains, as physiologically active constituents, the components a) phosphatidylserine and/or lysophosphatidylserine (in each case “PS”) and b) at least one (lyso)phospholipid different from component a) and c) a serine source different from component a), for example L-serine and/or O-phospho-L-serine. In this composition, the components a) and ... 01/04/07 - 20070003616 - Process for the production of an abuse-proofed dosage form The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N. ... 01/04/07 - 20070003615 - Nanoparticulate clopidogrel and aspirin combination formulations The present invention is directed to compositions comprising a nanoparticulate clopidogrel and aspirin combination, or salts or derivatives thereof, having improved clopidogrel bioavailability. The nanoparticulate clopidogrel particles, and optionally the nanoparticulate aspirin particles, of the composition have an effective average particle size of less than about 2000 nm and are ... 12/28/06 - 20060292220 - Compositions and methods for nutrition supplementation The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in ... 12/28/06 - 20060292219 - Sublingual buccal effervescent A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional ... 12/28/06 - 20060292218 - Agent having a destructive effect on malignant tumors and method for the production thereof Disclosed is an agent which has a destructive effect on malignant tumors and contains alpha-ketoglutaric acid, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and a compound that is capable of forming azomethine and is selected among the group 5-hydroxymethylfurfural, dehydroascorbic acid, maltol, and vanillin as an active substance, 5-hydroxymethylfurfural being preferred. The inventive agent can ... 12/21/06 - 20060286167 - Compositions and methods for the treatment of neurodegenerative diseases The invention features compositions and methods for the treatment of neurodegenerative diseases. ... 12/21/06 - 20060286166 - Tadalafil having a large particle size and a process for preparation thereof The present invention provides particulate tadalafil having a particle size of about 200 to about 600 microns and a process for controlling the particle size of tadalafil. ... 12/21/06 - 20060286165 - Taste-masked pharmaceutical particle, the preparation and use thereof The present invention provides a taste-masked pharmaceutical particle prepared by a polymer blending process, a process for preparing the particle, and the use of the particle in preparing the orally disintegrating tablets. In this process, a micronized active drug ingredient is mixed with three kinds of pharmaceutically acceptable polymer adjuvants ... 12/14/06 - 20060280792 - Attachment of a handle to a solid oral dosage form The present invention relates to a method of attaching a handle to a solid oral dosage form by use of high frequency mechanical vibrations. The present invention also relates to a method of attaching a handle to a solid oral dosage form, the method comprising: (a) placing a handle in ... 12/14/06 - 20060280791 - Pharmaceutical formulations The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. ... 12/14/06 - 20060280790 - Pharmaceutical formulations The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. ... 12/14/06 - 20060280789 - Sustained release formulations The invention provides sustained release formulations of basic drugs, stereoisomers of basic drugs, pharmaceutically acceptable salts of basic drugs, and pharmaceutically acceptable salts of stereoisomers of basic drugs. The basic drugs may be anti-dementia drugs, such as cholinesterase inhibitors or memantine. In one embodiment, the cholinesterase inhibitor is donepezil. ... 12/07/06 - 20060275365 - Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof The invention relates to immediate-release and high-drug-load solid pharmaceutical formulations comprising micronised (4-chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl] as well as pharmaceutically acceptable salts thereof. ... 12/07/06 - 20060275364 - Flexible solid dosage forms and methods of making and using the same The present invention provides flexible solid dosage forms that include an active agent, gelatin, and a polyol or saccharide. The present invention also provides methods of making flexible solid dosage forms. ... 12/07/06 - 20060275363 - Stable granulates containing s-adenosylmethionine and process for preparation thereof A fluid bed granulation process for manufacturing non-hygroscopic, stable granulates containing a water-soluble salt of S-adenosylmethionine is described. Said process comprises: a) the simultaneous, sequential or alternate dispersion of at least a solution of a water-soluble salt of SAMe (A) and of a solution of a coating agent (B), on ... 12/07/06 - 20060275362 - Rapidly-dissolving pharmaceutical composition for inhibiting ovulation A rapidly-dissolving oral dosage pharmaceutical composition for inhibiting ovulation in a mammal, said composition comprising drospirenone or a pharmaceutically acceptable salt or ester thereof, optionally ethinyl estradiol or a pharmaceutically acceptable salt, ester or ether thereof, a surfactant and at least one pharmaceutically acceptable excipient, wherein the drospirenone has a ... 11/30/06 - 20060269600 - Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient Dosage forms for oral administration of a PDE4 inhibitor whose solubility is slight are described. They contain PVP as a binder. ... 11/30/06 - 20060269599 - Fast-dissolving pharmaceutical composition A fast-dissolving pharmaceutical composition comprising micronized (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3′-pyrrolidine-1,2′,3,5′-tetrone (hereinafter, referred to as AS-3201). The present pharmaceutical composition has improved dissolution characteristics as well as a good bioavailability. ... 11/23/06 - 20060263425 - Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent A pharmaceutical composition, which composition comprises: an insulin sensitiser and another antidiabetic agent and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetes agent, and the use of such composition in medicine. ... 11/23/06 - 20060263424 - Pharmaceutical compositions comprising clavulanic acid A pharmaceutical composition comprising an active ingredient and clavulanate wherein the clavulanate is in the form of granulated and hydrophobised particles; and intermediates in its preparation, e.g. clavulanate in granulated and/or hydrophobised form. ... 11/23/06 - 20060263423 - Product and process for increasing compactibility of carbohydrates The present invention includes a method for preparing a highly compactible carbohydrate product, and the product itself. In one embodiment, a composition according to the present invention includes polyols. ... 11/16/06 - 20060257478 - Acid-gas absorbing tablet and method of use An acid-gas absorbing tablet including in relatively sufficient proportions an adsorbent which may be activated carbon or silica gel or a mixture thereof, potassium carbonate, polyvinylpyrrolidinone, and potassium bicarbonate. A method of absorbing acid gases from a confined environment utilizing the above tablet by inserting it into the confined environment. ... 11/16/06 - 20060257477 - Acid-gas absorbing tablet and method of use An acid-gas absorbing tablet including in relatively sufficient proportions an adsorbent which may be activated carbon or silica gel or a mixture thereof, potassium carbonate, polyvinylpyrrolidinone, and potassium bicarbonate. A method of absorbing acid gases from a confined environment utilizing the above tablet by inserting it into the confined environment. ... 11/16/06 - 20060257476 - Tablet formulation Disclosed is a non-sustained release pharmaceutical tablet composition which comprises a rapidly precipitating drug in an amount from about 5 to about 60% and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegrant in ... 11/16/06 - 20060257475 - Stable sertraline hydrochloride formulation and method Pharmaceutically stable solid pharmaceutical dosage forms of sertraline hydrochloride Form II and Form V polymorphs formed by direct compression. ... 11/16/06 - 20060257474 - Remedies for glomerular diseases The present invention relates to a preventive or therapeutic agent for a glomerular disease which comprises an anti-thrombocytic agent and an HMG-CoA reductase inhibitor as active ingredients. The above agent is useful for prevention and therapy of various glomerular diseases including chronic glomerular nephritis. ... 11/16/06 - 20060257473 - Extended release tablet A single tablet layer having an extended release profile comparable to the release profile of a bi-layer tablet having both an immediate release and an extended release layer is prepared from a pharmaceutical granulation containing a pharmaceutically active compound, a hydrophilic polymer, and a water in-soluble, non-swellable particulate channeling agent. ... 11/16/06 - 20060257472 - Stability of progestogen formulations In a preparation for hormone replacement therapy having a low content of progestogen, the stability of the progestogen component can be enhanced by using a cellulosic binder, for example hydroxypropylcellulose, in stead of a non-cellulosic binder. ... 11/16/06 - 20060257471 - Pharmaceutical tablets of crystalline type ii aripiprazole Crystalline aripiprazole Type II can be formulated into pharmaceutical tablets having reduced dissolution profile variability upon storage. ... 11/16/06 - 20060257470 - Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier The invention concerns a method for producing solid galenic formulations which consists in: forming a processable paste comprising a) 50 to 99.4 wt. % of at least one non-thermoplastic carrier, b) 0.5 to 30 wt. % of at least an adjuvant selected among thermoplastic polymers, lipids, sugar alcohols and solubilizing ... 11/09/06 - 20060251718 - Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby A pharmaceutical formulation of compounds with low aqueous solubility and method of manufacture thereof. The formulation may include a pharmacologically active compound having low aqueous solubility and starch in the amount of greater than about 25 weight percent. A manufacturing method may include blending the active compound and starch, compressing ... 11/09/06 - 20060251717 - Memantine oral dosage forms This invention relates to an oral dosage form containing between 1 mg and 100 mg of memantine, wherein said dosage form does not contain 10 mg of memantine or 20 mg of memantine, and wherein said dosage form is not prepared by the patient or a person administering the drug ... 11/09/06 - 20060251716 - Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the ... 11/09/06 - 20060251715 - Oral delivery of a botanical A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2, to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameters and stopping the extraction before all of the kavalactones have been extracted or allowing the extracted ... 11/09/06 - 20060251714 - Pharmaceutical formulations of amyloid inhibiting compounds Therapeutic formulations and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Therapeutic formulations and methods for preventing or treating amyloidosis and/or amyloid-related disease are also described. ... 11/02/06 - 20060246131 - Use of metformin to counteract weight gain associated with psychotropic medications A method for minimizing the weight gain side effect associated with ABILIFY® (aripiprazole) or GEODON® (ziprasidone) treatment is disclosed. In this method, metformin, a biguanide compound, is concurrently administered to a patient taking the ABILIFY® (aripiprazole) or GEODON® (ziprasidone) therapy. A pharmaceutical composition containing the combination of ABILIFY® (aripiprazole) or ... 11/02/06 - 20060246130 - Compositions and methods for combination antiviral therapy The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or ... 10/26/06 - 20060240102 - Binders for tablets with high strength based on finely divided vinyllactam polymers, the production and use thereof Finely divided binders in powder form composed of vinyllactam polymers, where the binders have an average particle size of up to 35 μm and an apparent density of less than 0.2 g/ml. ... 10/26/06 - 20060240101 - Orally disintegrating pharmaceutical tablet formulations of olanzapine This invention provides orally disintegrating pharmaceutical tablet formulations comprising per tablet the following ingredients in the following percentages by weight: olanzapine as an active ingredient in an amount from about 2.5% to about 10%; mannitol in an amount from about 75% to about 95%; a disintegrating agent in an amount ... 10/26/06 - 20060240100 - Dosage form containing pantoprazole as active ingredient Dosage forms for the oral administration of the magnesium salt of pantoprazole are described. ... 10/19/06 - 20060233876 - Compositions and methods for reducing cardiovascular morbidity and/or mortality The present invention is related to a method for reducing cardiovascular morbidity and/or mortality comprising administering a combination comprising an ACE inhibitor and a CCB, specifically benazapril and amlodipine besylate. ... 10/19/06 - 20060233875 - Taste masked sumatriptan tablets and processes for their preparation The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation. ... 10/12/06 - 20060228411 - Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs Pharmaceutical compositions having improved dissolution profiles for drugs therein is disclosed. ... 10/12/06 - 20060228410 - Flavored taste-masked pharmaceutical formulation made using a one-step coating process The present invention encompasses a flavored and taste-masked pharmaceutical composition comprising a plurality of pharmaceutically acceptable cores, such as microspheres, said pharmaceutically acceptable cores comprising etoricoxib, wherein the pharmaceutically acceptable cores are coated with a flavored taste-masking coating solution in a convenient one-step process. ... 10/12/06 - 20060228409 - Scored tablet An object of the present invention is to provide a dividable tablet that is easily and accurately divided without any particular limitation on dividing method thereof and has superior strength. That is, the present invention provides a dividable tablet whose lower surface is a curved surface gradually rising from the ... 10/05/06 - 20060222707 - Formulations of fenofibrate The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of a fibrate drug, preferably fenofibrate, intimately associated with a surfactant mixture, preferably a mixture comprising PGE 6000 and poloxamer 407. The invention also provides a method for the treatment ... 10/05/06 - 20060222706 - Formulations of fenofibrate The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with menthol or a surfactant mixture, wherein the menthol can be menthol or menthol surfactant mixture, and wherein the surfactant mixture can ... 10/05/06 - 20060222705 - Pharmaceutical tablet and apparatus and method for making A punch and die set include a die with a single large cavity which can receive dry particles of relatively large dimensions or large arching indexes as compared to the transverse dimensions of the tablets formed by the particles, e.g., 1.5 mm diameter and 1 mm height. The upper and ... 10/05/06 - 20060222704 - System and a method for labeling a substrate A method for labeling a substrate includes positioning the substrate adjacent to an inkjet material dispenser, and selectively jetting an edible ink onto the substrate with the inkjet material dispenser. The edible ink is configured to exhibit a known fluorescent emissive profile when exposed to a visible light. ... 10/05/06 - 20060222703 - Pharmaceutical composition and preparation method thereof The invention relates to an oral solid pharmaceutical composition comprising pharmacologically effective amounts of entacapone, levodopa and carbidopa, or a pharmaceutically acceptable salt or hydrate thereof, and one or more pharmaceutically acceptable excipients, wherein the excipients are long-chain polymers having an equilibrium moisture content of at least 2%, and to ... 10/05/06 - 20060222702 - System and method for optically tracking objects using a spectral fingerprint of fluorescent compounds A method for labeling a substrate includes positioning the substrate adjacent to an inkjet material dispenser, and selectively jetting an edible ink onto the substrate with the inkjet material dispenser. The edible ink is configured to exhibit a known fluorescent emissive profile when exposed to an ultraviolet light. ... 09/28/06 - 20060216349 - Ibuprofen composition Fumaric acid is added in amounts sufficient to reduce the burn sensation commonly associated with propionic acid derivatives. ... 09/28/06 - 20060216348 - Agglomerated starch compositions Agglomerated starch compositions containing native starch and pre-compacted starch powder is disclosed. The agglomerated starch compositions have superior flow and less pH sensitivity than simple blends of the two components at equivalent ratios. ... 09/28/06 - 20060216347 - Tablet punches and methods for tableting A tablet punch having a punch cup having a non-stick polymeric coating which may comprise a fluoropolymer such as polytetrafluoroethylene. ... 09/28/06 - 20060216346 - Dosage form containing (s)-pantoprazole as active ingredient Dosage forms for the oral administration of the magnesium salt of (S)-pantoprazole are described. ... 09/21/06 - 20060210628 - Use of epinine for enhancing physical performance A method of decreasing fat and adipose tissue, and increasing alertness in humans comprises administering epinine in a daily dosage between about 50 and 300 mg. Epinine may be administered once per day or in multiple doses, either alone or in combination with other compounds and mixtures. ... 09/21/06 - 20060210627 - Direct compression formulation and process This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof, to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process ... 09/21/06 - 20060210626 - Radio frequency identification pharmaceutical tracking system and method An ingestible dosage form includes a pill containing a pharmaceutical content and an RF tag associated with the pill. The RF tag is configured to output a wireless response signal in response to a wireless excitation signal received by the RF tag from an RF reader. The ingestible dosage form ... 09/21/06 - 20060210625 - Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms An oral pharmaceutical composition, comprising one or more positively charged, highly water-soluble pharmaceutically active agents such as trospium chloride, and one or more polymers containing polarized oxygen atoms, whereby the active agent(s) form an ion-dipole interaction with the polymer(s) that may be used for an immediate release system, an extended ... 09/21/06 - 20060210624 - Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of p Medicament comprising, in a pharmaceutically acceptable vehicle, an anti-psychotic or an antidepressant (A), which, on its own, has an undesirable effect of a gain in body weight or sedation, and an antagonist and/or inverse agonist (B) of the histamine H3 receptor, the antagonist and/or inverse agonist of the histamine H3 ... 09/14/06 - 20060204572 - Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives The present invention provides solid dispersions or solid dispersion pharmaceutical preparations containing a water-soluble polymeric substance(s) and a phenylalanine compound of the formula (1) or pharmaceutically acceptable salts thereof, wherein A represents the formula (2) and the like, B represent an alkoxy group and the like, E represents a hydrogen ... 09/14/06 - 20060204571 - Stable compositions of bupropion or its pharmaceutically acceptable salts A stable oral pharmaceutical composition comprising a therapeutically effective amount of bupropion or its pharmaceutically acceptable salt intimately blending with one or more compatible excipients selected from the group consisting of talc and potassium chloride, additional pharmaceutically acceptable excipients and total impurities are present in amounts from 0% to not ... 09/14/06 - 20060204570 - Preparing method for controlled released type tablet tamsulosin hcl and the tablet thereof The present invention relates to a simple and effective method for preparing a tamsulosin HCl sustained-release tablet and a tamsulosin HCl sustained-release tablet produced thereby. The method comprises the steps of: dissolving tamsulosin HCl as an active ingredient in an organic solvent; dissolving the tamsulosin HCl solution in hydroxypropylmethylcellulose phthalate ... 09/14/06 - 20060204569 - Functional starch powder Functional starch powder of 400% or more water retention capacity, 5 hr or more collapse time and 200 g or more gel indentation load. This functional starch powder is produced through the step of heating a starch raw material in the presence of water at 60 to 150° C. so ... 09/14/06 - 20060204568 - Oral pharmaceutical preparation for proton pump antagonists The invention relates to novel dosage forms for proton pump antagonists. ... 09/07/06 - 20060198885 - Oral pharmaceutical composition An oral pharmaceutical composition having reduced bitterness comprising therapeutically effective amounts of cetirizine or its pharmaceutically acceptable salts, alkaline earth oxide and a pharmaceutically acceptable carrier comprising a disintegrant wherein the composition disintegrates rapidly in the oral cavity. ... 09/07/06 - 20060198884 - Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following ... 08/31/06 - 20060193910 - Tablets with improved drug substance dispersibility The present invention relates to a method for the preparation of pharmaceutical compositions in the form of tablets with improved drug substance dispersibility, which method comprises a) preparing a dispersion of at least one pharmaceutically active drug substance and at least one surfactant and/or binder in a liquid; b) preparing ... 08/31/06 - 20060193909 - Breath freshening pressed tablets and methods of making and using same A confectionery product comprises a pressed tablet made from a compressible composition and having at least one abrasive surface suitable for cleaning the surface of a human tongue in an oral cavity. Typically the product has a first side and a second side generally opposite to the first side; the ... 08/31/06 - 20060193908 - Extended release formulations of poorly soluble antibiotics An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release ... 08/24/06 - 20060188571 - Vaginally administrable progesterone containing tablets and method for preparing the same The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the ... 08/24/06 - 20060188570 - Compressed tablet formulation This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS. ... 08/24/06 - 20060188569 - Stable pharmaceutical formulations of zonisamide and methods for their manufacture One of the embodiments of the present invention is directed toward a process for preparing a stable zonisamide pharmaceutical composition, comprising subjecting zonisamide to wet granulation with a granulation liquid to form a granulated mixture as the stable zonisamide pharmaceutical composition, wherein the granulation liquid is selected from purified water, ... 08/24/06 - 20060188568 - Stable formulations of ace inhibitors and methods for preparation thereof Stabilized pharmaceutical solid composition of ACE inhibitor comprising an ACE inhibitor and a selective dosage formulation thereof comprising of meglumine. The ACE inhibitor selectively combined with a dosage form including essentially the meglumine is surprisingly found to avoid the degradation of ACE inhibitor by such dosage forms especially the commonly ... 08/17/06 - 20060182802 - Rapidly disintegrable solid preparation A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness. ... 08/17/06 - 20060182801 - Sequestered antagonist formulations Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the ... 08/17/06 - 20060182800 - Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions The present invention relates to pharmaceutical compositions of antihistamine-decongestant combination. Specifically the invention relates to bilayered tablet formulation comprising antihistaminic decongestant combination. More specifically present invention relates to the novel polymorph of fexofenadine or pharmaceutically accepted salts thereof, with at least one decongestant in the form of bilayered tablet. The ... 08/17/06 - 20060182799 - Tabletting process The invention refers to a process for the preparation of a self-dispersing or self-emulsifying tablet, wherein a heated granulation mixture containing an active lipophilic substance and a surfactant is granulated into granules, said granules are cooled to a semi-solid state, said semi-solid granules are mixed with one or more fillers ... 08/10/06 - 20060177504 - Combination pain medication This patent is an evolution of previous combination medication patents. Previous combination patents such as U.S. Pat. No. 6,613,354 which is a combination of an NSAID and Proton Pump Inhibitor. Thus the previous patents have covered gastrointestinal prophylaxis but none has covered both gastrointestinal and cardiovascular prophylaxis. This is likely ... 08/10/06 - 20060177503 - Bambuterol and integrin inhibitor combination and treatment method The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of bambuterol, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms ... 08/10/06 - 20060177502 - Sustained release pharmaceutical formulations Disclosed are novel ranolazine sustained release pharmaceutical formulations. ... 08/10/06 - 20060177501 - Film coated tablets containing ibuprofen The invention relates to film-coated tablets containing ibuprofen lysinate with improved stability, bioavailability and higher acceptance (compliance) in patients, and the use of these film-coated tablets for preparing a pharmaceutical composition for the treatment of acute and/or chronic pain. ... 08/10/06 - 20060177500 - Solid dispersion of tacrolimus The present invention relates to the carrier of the solid dispersion of tacrolimus, which is prepared by using the solid surfactant having a property of HLB value higher than or equal to about 7. The surfactants carry out a function of a carrier and a function of a dissolution enhancer, ... 08/10/06 - 20060177499 - Method for the manufacture of a pharmaceutical composition in the form of tablets containing a fibrate and tablets obtained according to the method A method for the manufacture of a pharmaceutical composition containing the active ingredient fenofibrate or one of its derivatives, optionally in combination with a second active ingredient, in the form of tablets, characterized in that it comprises a compression step of the active ingredient and excipients by means of a ... 08/10/06 - 20060177498 - Solid pharmaceutical composition comprising ramipril The present invention relates to solid pharmaceutical compositions comprising ramipril with a suitably low water content, and processes for preparing said compositions. ... 08/03/06 - 20060172005 - Tablet and process for producing the same An object of the present invention relates to a tablet which comprises an active ingredient and a cyclodextrin or a cyclodextrin derivative and rapidly disintegrates in the oral cavity, etc. The present invention provides a tablet in which 70% by mass or more of the components of the tablet is ... 07/27/06 - 20060165785 - Method of chemically stabilizing pharmaceutical formulations with cholesterol The invention relates to a method of improving the chemical stability of an active ingredient substance in a particulate formulation in chemically reactive environment comprising associating the active ingredient substance with a chemically stabilising amount of cholesterol to form composite particles comprising said active ingredient substance and cholesterol. ... 07/27/06 - 20060165784 - Calcium supplement A dissoluble oral tablet of calcium supplement and the method of making the product are provided. This calcium supplement comprises an exposure area and a coating covered area. The surface ratio between the exposure area and the coating covered area is about 1:1 to 1:12. The exposure area can be ... 07/27/06 - 20060165783 - Compacted lactic acid menthyl ester The invention relates to lactic acid menthyl ester compacts, a method for the preparation of lactic acid menthyl ester compacts and the use thereof. ... 07/27/06 - 20060165782 - Solid compositions comprising gabapentin having improved stability Solid pharmaceutical compositions of improved stability which comprise gabapentin and a basic compound that is a hydroxide or a salt of a weak acid. ... 07/27/06 - 20060165781 - Orally disintegrating tablets and process for obtaining them The tablets comprise: at least 59.5% spray-dried mannitol; active ingredient below or equal to 10%, where at least 90% in weight of the active ingredient has a particle size below 100 μm; microcrystalline cellulose 10-18%, with an average particle size of 50 μm and where at least 99% in weight ... 07/27/06 - 20060165780 - Anticoagulant composition A solid heparin tablet composition has a melting point of 25° C. or higher and is a continuous lipid component containing one or more polar lipids, one or more non-polar lipids, optionally one or several of water and mono- to trivalent alcohol in an amount of up to 15% by ... 07/27/06 - 20060165779 - Novel method stabilizing bupropion hydrochloride tablets The present invention relates to a stable bupropion hydrochloride tablet and a method of stabilizing bupropion hydrochloride tablets, which also serves as an improved tabletting process for the preparation of sustained release bupropion hydrochloride tablets. ... 07/20/06 - 20060159750 - Pharmaceutical dosage form bearing pregnancy-friendly indicia A pharmaceutical dosage form comprising at least one active ingredient and destined for administration to pregnant women. The pharmaceutical dosage form bears pregnancy-friendly indicia apt to improve patient compliance with medically recommended dosage regimen resulting in improved product effectiveness. The pregnancy-friendly indicia is also apt to diminish the incidence of ... 07/20/06 - 20060159749 - Controlled release and taste masking oral pharmaceutical composition Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution ... 07/20/06 - 20060159748 - Oral immediate release formulation of a poorly water-soluble active substance The invention is related to an oral immediate release formulation of Benzazepin-1-acetic acid derivatives comprising a) said active substance in an amount of up to 65% of the total weight of the formulation; b) at least 10% w/w an alkaline compound or a mixture of alkaline compounds; c) between 0.1 ... 07/20/06 - 20060159747 - Telmisartan and hydrochlorothiazide combination therapy A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of hydrochlorothiazide, and methods of treating hypertension in patients with such combination. ... 07/20/06 - 20060159746 - Compositions comprising fatty acids and amino acids The invention relates to a combination, such as a combined preparation or pharmaceutical or nutritional composition, respectively, which comprises at least one cis-polyunsaturated fatty acid, at least one amino acid, and optionally at least one diabetes medicine for simultaneous, separate or sequential use in the prevention, delay of progression or ... 07/13/06 - 20060153913 - Solid formulation with improved solubility and stability, and method for producing said formulation The present invention relates to a solid formulation with improved solubility and maintained stability including a chemical substance poorly soluble in water as a pharmaceutically active ingredient formulated in an improved manner. More specifically, the present invention relates to a solid formulation having improved water-solubility which comprises a chemical substance ... 07/13/06 - 20060153912 - Choline ascorbate formulations The invention relates to novel choline ascorbate-containing formulations; processes for their preparation and their use in human or animal foods, or human or animal food supplements or pharmaceuticals. ... 07/06/06 - 20060147525 - Lipophilic drug compositions The invention is directed to biologically active lipophilic compositions comprising a biologically active covalently attached to, or encapsulated within, a lipid. Preferably, a biologically active agent is both covalently attached to a lipid and encapsulated within a lipid composition. Preferred lipid components include triglycerides and fatty acids. The resulting composition ... 07/06/06 - 20060147524 - Melt-formulated, multi-particulate oral dosage form A melt-formulated, multiparticulate, oral dosage form containing clavulanic acid and/or at least one physiologically acceptable salt thereof and at least one sucrose fatty acid ester and optionally further physiologically acceptable auxiliary substances; a process for producing such a dosage form, combination dosage forms with β-lactam antibiotics, and the pharmaceutical use ... 07/06/06 - 20060147523 - Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof A nutritional supplement composed of phytosterols, anti-oxidants, and other complexes, including essential fatty acids, amino acids, peptides, proline rich polypeptides and digestive enzymes is described. The nutritional supplement may be used by individuals suffering from or at risk of developing immune system diseases; breast cancer, colon and prostate cancer; HIV ... 07/06/06 - 20060147522 - Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed ... 07/06/06 - 20060147521 - Sustained release ranolazine formulations A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and ... 07/06/06 - 20060147520 - Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation Microparticles comprising iloprost are disclosed. In some embodiments, the microparticles are used to treat pulmonary hypertension. Devices comprising the microparticles are also disclosed. Combination therapies utilizing the microparticles are also provided. ... 07/06/06 - 20060147519 - Process for the preparation of robust formulations of valacyclovir hydrochloride tablets The invention relates to robust formulations of valacyclovir hydrochloride tablets. A robust tablet includes a hydrated form of valacyclovir hydrochloride having a water of hydration content of more than approximately 3% w/w and a particle size of less than approximately 355 μm. ... 06/29/06 - 20060141031 - Orally disintegrating pharmaceutical compositions with sensory cue agents The present invention relates to pharmaceutical compositions that disintegrate in the mouth and include at least one systemically active pharmaceutical ingredient in a therapeutically effective amount and at least one sensory cue agent in a sensory effective amount. ... 06/29/06 - 20060141030 - Method and composition for stable and controlled delivery of (-)-hydroxycitric acid The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable ... 06/29/06 - 20060141029 - Methods and compositions for delivery of catecholic butanes for treatment of diseases The present invention provides kits, methods and compositions for the treatment of diseases, such as, for example, non-cancer proliferative diseases, neurodegenerative diseases, diabetes and hypertension. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA Compounds in a pharmaceutically acceptable carrier or ... 06/29/06 - 20060141028 - Cyclosporin formulations The present invention relates to compositions comprising solutions of drugs in menthol, especially drugs that are poorly soluble in water, and to methods for making such compositions. ... 06/29/06 - 20060141027 - Sublingual administration of non-steroidal anti-inflammatory pharmacological substances The present invention relates to a sublingual administration method of non-steroidal ant-inflammatory, referred as FANS, which allows to considerably reduce the therapeutic dose, with the additional advantage of increasing the quickness of the effects and improving the tolerability. ... 06/22/06 - 20060134205 - Process for preparing a pharmaceutical composition A method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions results in a favored pharmaceutical product. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid ... 06/22/06 - 20060134204 - Complexes made using low solubility drugs Disclosed herein are substances that include a complex that includes a drug moiety ionically bound to a counter-ion; wherein a solubility of the complex is greater than a solubility of the drug moiety. Also disclosed are compositions and dosage forms made from such substances and complexes; methods of making compositions, ... 06/22/06 - 20060134203 - Pharmaceutical compositions The present invention provides a pharmaceutical composition in solid form comprising a poorly water soluble drug, a solubilizing component, and a surfactant which is semisolid or solid. The poorly soluble drug may e.g. be a cyclosporin or a macrolide. ... 06/22/06 - 20060134202 - Homeopathic sublingual dosage forms and methods thereof A sublingual dosage form comprises an inert preformed tablet including at least one excipient and at least one wicking agent, with the at least one wicking agent adapted to selectively absorb at least one solvent-borne medicating ingredient from one portion of the inert preformed tablet into another portion of the ... 06/22/06 - 20060134201 - Collagen troches for treating mouth lesions A soluble/erodable troche for delivering collagen in the mouth for treatment of mouth lesions. The collagen may be gelatin from animal skins. The structure of the troche may be formed with a porous network that remains solid at human mouth temperatures and slowly dissolves/erodes in saliva. In some embodiments, the ... 06/22/06 - 20060134200 - Pharmaceutical composition based on agonist of benzodiazepine The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration, including as active ingredient thereof, an agonist of the central receptor of benzodiazepinics chosen among diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam and midazolam maleate, in a mixture with a pharmaceutical excipient consisting of, at ... 06/22/06 - 20060134199 - Tablet quickly melting in oral cavity The object of the present invention is to provide, as a solid preparation for making it easy to take, thus improving patient's compliance etc., an intraorally rapidly disintegrating tablet which can be produced easily without any particular problem by a usual method of producing tablets with a usual tabletting machine, ... 06/22/06 - 20060134198 - Pharmaceutical compositions with improved dissolution The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining ... 06/22/06 - 20060134197 - Method of reducing unpleasant taste and/or unpleasant odor The present invention has objects to provide a method of lowering the unpleasant taste and/or smell of compositions, and an agent for lowering unpleasant taste and/or smell. The objects are solved by providing a method of lowering unpleasant taste and/or smell, comprising a step of incorporating an saccharide derivative of ... 06/22/06 - 20060134196 - Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the ... 06/22/06 - 20060134195 - Mannose-based fast dissolving tablets Fast-dissolving pharmaceutical tablets comprising mannose are described. The mannose component imparts both structure-forming and fast-dissolution properties to the tablets. Granulation of tablet components and humidification forms strong liquid bridges at the surface interfaces of mannose particles, which leads to strengthened tablets. The mannose particles, however, remain porous following compression so ... 06/22/06 - 20060134194 - Formulations containing substituted imidazole derivatives Improved formulations containing substituted imidazole derivatives of the general formula 1, formula (I) wherein Y is —CH2— or —CO—, R1 is H, halo or hydroxy, R2 is H or halo, and R3 is H or lower alkyl (e.g. C1 to C4 alkyl, preferably C1 or C2 alkyl), or a pharmaceutically ... 06/22/06 - 20060134193 - Method to improve pharmaceutical tablets having a matrix of cellulose ether This invention provides for a packaged tablet, which tablet has a matrix consisting of at least 55% of a cellulose ether, whereby the tablet has a water activity of at most 0.6 and is packaged such as to delay moisture uptake by the tablet in order to decrease the vulnerability ... 06/22/06 - 20060134192 - Method of stabilizing diarylvinylene compound The present invention provides, for example, a method for stabilization of a diarylvinylene compound such as a compound represented by the above formula (I) or the like, or a pharmaceutically acceptable salt thereof in a solid formulation containing the diarylvinylene compound or the pharmaceutically acceptable salt thereof, which comprises allowing ... 06/22/06 - 20060134191 - Immediate-release pharmaceutical dosage form comprising polymorphous tibolone An immediate-release pharmaceutical dosage form comprising, as the active substance, polymorphous tibolone and pharmaceutically acceptable excipients, wherein the polymorphous tibolone has a mean particle size as defined in the specification of below 22.8 μm in the dosage form. ... 06/15/06 - 20060127475 - Nateglinide-containing preparation The present invention provides a small-sized preparation that is easy to take, containing 26% or more of nateglinide and 28% or more of at least one disintegrant selected from the group consisting of carmellose or salts thereof, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, partly pregelatinized starch and low-substituted hydroxypropyl cellulose, ... 06/15/06 - 20060127474 - Pharmaceutical compositions comprising fluvastatin Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage. ... 06/15/06 - 20060127473 - Compositions and methods for stabilizing active pharmaceutical ingredients The present invention relates to stable pharmaceutical compositions having an unstable active pharmaceutical ingredient. ... 06/15/06 - 20060127472 - Taste-masked prednisolone oral formulations An improved taste-masked pharmaceutical prednisolone composition contains prednisolone sodium phosphate taste-masked with an effective taste-masking amount of rum ether. ... 06/08/06 - 20060121111 - Formulations of substituted benzoxazoles The present invention provides solid dosage formulations of benzoxazole-containing ERβ-selective ligands, and processes for their manufacture. ... 06/08/06 - 20060121110 - Formulations of substituted benzoxazoles The present invention relates to solid dosage formulations that include ERβ-selective ligands that contain benzoxazole, and processes for manufacture of said formulations, more particularly to novel formulations and processes for manufacture of formulations containing the ERβ-selective ligand, ERB-041. ... 06/08/06 - 20060121109 - Formulations of substituted benzoxazoles The present invention provides solid dosage formulations of benzoxazole-containing ERβ-selective ligands, and processes for their manufacture, more particularly to novel formulations, and processes for their manufacture, that contain the ERβ-selective ligand, ERB-041. ... 06/08/06 - 20060121108 - System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride The formulation and method of producing a directly compressible pharmaceutical composition that has metformin as an active ingredient. To produce the pharmaceutical composition, a binding solution of povidone, starch and water is created. The binding solution is then mixed with a high concentration of metformin HCl to form a first ... 06/08/06 - 20060121107 - Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is ... 06/01/06 - 20060115529 - Fast-melting tablets having taste-masking and sustained release properties Fast-melting tablets contain particles of an active ingredient and ion-exchange resin complex to mask unpleasant taste associated with the active ingredient. The resin complex particles can be coated or uncoated to impart sustained release properties to the active ingredient. A fast-melting tablet also comprises a dry binder and bulk diluent ... 06/01/06 - 20060115528 - Rapidly disintegrating tablet The present invention relates to rapidly disintegrating tablets intended to be used as orodispersible tablets or dispersible tablets. They are ingested either by dispersing directly in the mouth or in water. The tablets include silicified microsrystalline cellulose. They are especially suitable for antibiotics. These tablets are also suitable for use ... 05/25/06 - 20060110453 - Calcium hypochlorite blended tablets A non-Division 5.1 Oxidizer tablet consisting essentially of a blend of hydrated calcium hypochlorite with magnesium sulfate heptahydrate, wherein the blend contains at least about 17% by weight of water based on the total weight of the blend; contains from about 0.1% to about 10% of lime based on the ... 05/25/06 - 20060110452 - Dosage forms of risedronate Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine ... 05/25/06 - 20060110451 - Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives The present invention provides solid dosage formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives and processes for their manufacture. In some particular embodiments, the present invention provides novel formulations of the antipsychotic and antiobesity agent (9aR,12aS)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline hydrochloride (Compound A.HCl). ... 05/25/06 - 20060110450 - Bilayer tablet of telmisartan and amlodipine A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for instant release of the calcium channel blocker amlodipine from a disintegrating or eroding tablet matrix. ... 05/25/06 - 20060110449 - Pharmaceutical composition The present invention relates to formulations useful for treating respiratory disorders associated with the production of mucus glycoprotein, skin disorders, and allergic conjunctivitis while substantially reducing adverse effects associated with the administration of non-selective anti-cholinergic agents and methods of use thereof. ... 05/25/06 - 20060110448 - Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a local anaesthetic such as lidocaine, polidocanol or prilocaine are provided, which are useful in particular in the treatment of dermatological diseases such as atopic, contact or seborrhoeic dermatitis, psoriasis, acne, rosacea, post-peel, pruritus, skin burning, or ... 05/25/06 - 20060110447 - Controlled and continued delivery of rifaximin and/or other substances A gum-like device is designed for the controlled and continued delivery of rifaximin, without producing the usually intense red coloration, for the resolution of the infections and the reduction of the inflammation in the oral cavity and in the laryngo-pharyngeal one. The device also protects either the gum or the ... 05/25/06 - 20060110446 - Deferacirox dispersible tablets The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet. ... 05/25/06 - 20060110445 - Dispersible tablet for oral administration The present invention relates to a process for the preparation of a dispersible tablet dosage form comprising β-lactam antibiotics for oral administration. ... 05/25/06 - 20060110444 - Solid dosage form comprising a fibrate The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations. ... 05/18/06 - 20060105035 - Sustained release heterodisperse hydrogel systems for insoluble drugs A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic ... 05/11/06 - 20060099253 - Antibiotic product formulation This invention discloses an antibiotic formulation in an immediate release antibiotic dosage form, comprising an antibiotic, colloidal silicon dioxide, povidone, silicified microcrystalline cellulose, croscarmellose sodium, magnesium stearate and a coating, said formulation having a release profile wherein the Cmax is reached in less than five hours. ... 05/11/06 - 20060099252 - Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby A pharmaceutical formulation of compounds with low aqueous solubility and method of manufacture thereof. The formulation may include a pharmacologically active compound having low aqueous solubility and starch in the amount of greater than about 25 weight percent. A manufacturing method may include blending the active compound and starch, compressing ... 05/11/06 - 20060099251 - Formulations of finasteride This invention relates to pharmaceutical formulations of finasteride that include Gelucire®. ... 05/11/06 - 20060099250 - Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets The use of an aqueous solution of citric acid and a highly water-soluble sugar as a binder for the granulation of tablet excipients. ... 05/11/06 - 20060099249 - Modified release formulations of at least one form of tramadol The present invention provides for a modified release pharmaceutical composition comprising at least one form of tramadol selected from the group consisting of tramadol, enantiomers thereof, pharmaceutically acceptable salts thereof and combinations thereof, the composition exhibiting an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm ... 05/04/06 - 20060093669 - Calcium hypochlorite blended tablets A non-Division 5.1 Oxidizer tablet consisting essentially of a blend of hydrated calcium hypochlorite with magnesium sulfate heptahydrate, wherein the blend contains at least about 17% by weight of water based on the total weight of the blend; contains from about 0.1% to about 10% of lime based on the ... 05/04/06 - 20060093668 - Melt granulated composition and modified release dosage form prepared from said composition Solid modified release dosage forms, prepared from melt granulated compositions comprising (A) one or more hydrophilic cellulose ether polymers, (B) a hydrophilic melt binder, and (C) a therapeutically active ingredient. ... 05/04/06 - 20060093667 - Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency A method for manufacturing a pharmaceutical composition having uniform drug distribution and potency is described which utilizes silicon dioxide to reduce the loss of active ingredient during the manufacturing process. The method is particularly useful for the manufacture of low dosage tablet compositions. ... 05/04/06 - 20060093666 - Formulations for tyrosine kinase inhibitors The present invention is related to a powder, powder blend or granulation formulation of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one, a tyrosine kinase inhibitor, which is adapted for reconstitution with a diluent. This invention is also related to a prepared aqueous suspension, or dispersion, formulation, particularly to a stable oral pharmaceutical formulation, comprising granules of ... 05/04/06 - 20060093665 - Method to improve surface properties of pharmaceutical tablets The invention provides a method to improve surface properties of tablets having a matrix consisting of at least 55% of a cellulose ether, characterised in that the method comprises briefly exposing the tablets to a hydrous solvent. ... 04/27/06 - 20060088594 - Highly compressible controlled delivery compositions of metformin Highly compressible controlled delivery compositions of metformin or salts thereof and the process of making the same are disclosed. Metformin is granulated with a binder and further dispersed in a rate-controlling matrix that results in increased hardness and decreased friability thereby effectively solving compressibility difficulties arising for Metformin formulations. ... 04/27/06 - 20060088593 - Dosage forms having a microreliefed surface and methods and apparatus for their production The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of ... 04/27/06 - 20060088592 - Oral formulation for delivery of poorly absorbed drugs A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption ... 04/27/06 - 20060088591 - Tablets from a poorly compressible substance A solid composition suitable for forming into a tablet includes a pharmaceutically active substance in an amount sufficient to provide a therapeutic effect when administered; from about 0.2 to about 15 weight %, based on the total weight of the composition, of a water-soluble preparation of a fat-soluble vitamin; and ... 04/20/06 - 20060083785 - Large dose ribavirin formulations The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin. ... 04/20/06 - 20060083784 - Amorphous pharmaceutical compositions The present invention is directed to use of electrospinning, i.e. the process of making polymer nanofibers from either a solution or melt under electrical forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers. The present invention is also directed to the process of making solid dispersions of ... 04/13/06 - 20060078613 - Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at ... 04/13/06 - 20060078612 - Chewable enteric coated aspirin tablets The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener. ... 04/13/06 - 20060078611 - Enteric coated aspirin granules comingled with binder The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated granule comprising an intimate mixture of an aspirin active ingredient and at least one binder capable of preferentially absorbing ambient moisture. ... 04/13/06 - 20060078610 - Method for producing pharmaceuticals or food supplements comprising pigmented polymer coatings The invention relates to a method for producing pharmaceuticals or parts thereof or food supplements or parts thereof, by coating substrates with a film-forming coating agent containing a pigment which is incompatible with the coating agent. The invention also relates to appliances for carrying out said method, especially a drum ... 04/13/06 - 20060078609 - Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base The invention provides a novel pharmaceutical composition comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug compound ratio is at least 1:1 by weight. ... 03/30/06 - 20060068008 - Lyophilized pharmaceutical compositions Pharmaceutical compositions that include a poorly water-soluble therapeutic compound, an aqueous solvent, a nonvolatile cosolvent and a bulking agent. The pharmaceutical compositions can be orally ingested or administered parenterally. The pharmaceutical compositions can further be lyophilized to form a pharmaceutically acceptable cake that can be administered orally, e.g., as a ... 03/30/06 - 20060068007 - Class of surfactant-like materials This invention generally refers to a novel class of surfactant-like material that promotes the solubility of poorly soluble compounds. ... 03/30/06 - 20060068006 - Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same An edible product such as a unit dosage form of a pharmaceutically active substance includes a layer of a material that can receive and retain a high resolution microrelief that can convey information. The microrelief is themo-formable, preferably formed from an aqueous solution of HPMC and/or HPC plus a plasticizer ... 03/30/06 - 20060068005 - Chewable electrolyte tablet A chewable electrolyte tablet. The chewable electrolyte tablet includes an agent to prevent stomach irritation, a flavoring agent, a sweetening agent, or a combination thereof to enable the tablet to be palatable and, therefore, ingested through simple mastication and without the need for water, thereby permitting the amount of water ... 03/30/06 - 20060068004 - Buccal delivery of sea cucumber tablets This invention is directed to a composition and method for the buccal delivery of sea cucumber extract. The composition for the buccal delivery of sea cucumber extract comprises a substantially uniform mixture of an effective amount of sea cucumber extract and sugar. In one embodiment of the invention, the sea ... 03/30/06 - 20060068003 - System for increasing compliance with medication regime A drug-dispensing arrangement for dissociating side effects, particularly gastrointestinal side effects, such as nausea and/or vomiting, from oral ingestion of a medication eliminates the development of learned taste-aversion. If a large, random and unpredictable order of flavors, and preferably well-known and pleasant flavors, are experienced by a patient in conjunction ... 03/23/06 - 20060062848 - Formulation comprising itraconazole Formulations of azole antifungals such as itraconazole and particularly formulations, co-formulations and compositions of itraconazole with one or more oligomeric and/or polymeric excipients are disclosed. Methods for preparation of the formulations, co-formulations and compositions include co-precipitating the two materials from a common solvent or solvent mixture using a compressed (typically ... 03/23/06 - 20060062847 - Pharmaceutical dosage forms with impeded extractability of a sympathomimetic d) 10 to 70% by weight of an alkali metal or alkaline earth metal salt of a mineral acid, of a sulfonic acid or of a C2-C6 carboxylic acid or mixtures thereof, where the total of components a) to d) is 100% by weight, where the ratio of active ingredient ... 03/23/06 - 20060062846 - Alfuzosin tablets and synthesis A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride anhydrate, ... 03/23/06 - 20060062845 - Alfuzosin tablets and synthesis A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride, lactose ... 03/23/06 - 20060062844 - Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles The present invention relates to a coated particle of active substance comprising a core, said core comprising the active substance and an acidic compound, said core being coated with a taste masking coating based on a polymer which is soluble at pH of 5 or less, and which is permeable ... 03/16/06 - 20060057196 - Efavirenz tablet formulation having unique biopharmaceutical characteristics The present invention provides an efavirenz tablet formulation which, when administered as a single dose to a subject, provides a mean maximum plasma concentration (Cmax) of about 4 μM to about 14 μM, a mean time of maximum plasma concentration (Tmax) of about 2 hours to about 5 hours, and ... 03/16/06 - 20060057195 - Stable solid preparations It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming ... 03/09/06 - 20060051415 - Method of enhancing absorptions of transmucosal administration formulations Disclosed is a method for enhancing absorption of a medicament that is suitable for administering transmucosally to a subject by providing an environment of the administration with a suitable pH. A medicament of propranolol suitably administered sublingually is provided. The medicament of propranolol can be used for treating diseases related ... 03/09/06 - 20060051414 - Fast water-dispersible domperidone tablets The present invention relates to fast water-dispersible tablets containing domperidone for oral administration. The formulations comprise domperidone or pharmaceutically acceptable salts thereof, about 60-80% of a “auxiliary” granulate (w/w), and about 10-30% of microcrystalline cellulose (w/w), expressed in relation to the total weight of the tablets, a sweetener, a flavouring ... 03/09/06 - 20060051413 - Method of enhancing absorptions of transmucosal administration formulations Disclosed is a method for enhancing absorption of a medicament that is suitable for administering transmucosally to a subject by providing an environment of the administration with a suitable pH. A medicament of propranolol suitably administered sublingually is provided. The medicament of propranolol can be used for treating cardiovascular diseases. ... 03/09/06 - 20060051412 - Method for producing an immediately decomposing oral form of administration which releases active ingredients The invention relates to a method for producing an oral form of administration which decomposes immediately and releases active ingredients in the mouth. According to said method, (a) an anionic pharmaceutical active ingredient is intensively mixed with (b) a copolymer consisting of radically polymerized C1-C4 esters of the acrylic acid ... 03/09/06 - 20060051411 - Antibacterial medicinal composition of enhanced oral absorptivity An objective of the present invention is to provide a cefditoren pivoxil pharmaceutical preparation which can safely be administered to a patient and not only improves wettability of cefditoren pivoxil, but also further improves absorbability through the intestinal tracts by maintaining amorphous particles having a high oral absorbability in a ... 03/09/06 - 20060051410 - Pharmaceutical composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid A highly stable pharmaceutical composition which comprises a mixture comprising a substance selected from the group consisting of 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid, salts thereof, and esters thereof, and croscarmellose sodium. ... 03/02/06 - 20060045911 - Stable pharmaceutical formulations A stable oral pharmaceutical formulation comprising ramipril or its pharmaceutically acceptable salt and a stabilizing amount of an ammoniomethacrylate copolymer in a pharmaceutically acceptable carrier medium is described. ... 02/23/06 - 20060039969 - Extended release formulations of erythromycin derivatives Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin ... 02/23/06 - 20060039968 - Gabapentin tablets and method for their preparation The present invention is generally directed to methods for preparing stable gabapentin tablets by wet granulation. A wet granulation method for preparing gabapentin tablets includes forming a mixture by dry mixing of a first portion of a binder with the gabapentin, one or more excipients, or a combination of the ... 02/23/06 - 20060039967 - Amino acid-containing chewable The present invention provides a chewable tablet having an improved oral disintegration property, which is easily chewed and capable of containing a large amount of an amino acid depending on need, more specifically, a chewable tablet comprising an amino acid and an oral disintegration promoting agent. ... 02/16/06 - 20060034919 - High ibuprofen content granules and their preparation and their use in pharmaceutical dosage forms Described are granules composed at least of a substantial amount of ibuprofen, at least one pharmaceutically-acceptable super disintegrant, and at least one pharmaceutically-acceptable binder different from the super disintegrant(s), the super disintegrant(s) being substantially uniformly dispersed throughout the granules. The methods for preparing such granules are described. The granules are ... 02/16/06 - 20060034918 - Buoyant formulations of betaine An oral control release formulation for releasing at least one betaine after oral administration to a human, said formulation comprising at least one pharmaceutically acceptable means ensuring an at least partial floating of the formulation releasing at least one betaine in the gastro-intestinal tractus. ... 02/16/06 - 20060034917 - Coating of tablet cores A process for the coating of tablet cores, said tablet core comprising an effective amount of at least one pharmaceutically active compound, comprising spraying a coating solution or suspension comprising a sugar, or a starch, or a mixture of a sugar and a starch onto the tablets or tablet cores ... 02/16/06 - 20060034916 - Compositions and methods for nutrition supplementation The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in ... 02/16/06 - 20060034915 - Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor A formulation of dexamethasone is prepared by preparing a dilute aqueous suspension of dexamethasone in a viscosity increasing excipient such as starch. The suspension is sprayed onto base ingredients and the resultant mixture is dried to provide a granulation of uniform potency. ... 02/16/06 - 20060034914 - Direct compression polymer tablet core The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of ... 02/16/06 - 20060034913 - Multiplex drug delivery device A capsule or shell for oral administration at the onset of an acute adverse health event (e.g. chest pain). The shell has a plurality of impermeable enclosures in which dosage units are situated. The shell and impermeable enclosures, are made from materials which promptly disintegrate in the buccal, oral, lingual ... 02/16/06 - 20060034912 - Compositions and methods for nutrition supplementation The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in ... 02/16/06 - 20060034911 - New oral immediated release dosage form The present invention relates to a solid oral immediate release dosage form of a pharmaceutically active compound, N-[(1,2,3,4-tetrahydro-5-methyl-8-(4-methylpiperazin-1-yl)-2-naphthyl]-4-morpholinobenzamide, in the form of the free base or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing said dosage form, the use of said dosage form and a method ... 02/09/06 - 20060029666 - Particle embedded with chemical substances and method of producing a particle A particle embedded with chemical substances, especially with physiological activity substances, is disclosed. The particle has (a) the embedded substances, embedded in base materials and ranged from about 0.1 to 70% by weight based on the total weight of the particle; and (b) the base material, selected from hydrogenated plant ... 02/09/06 - 20060029665 - Pilocarpine compositions and methods of use thereof The present invention provides novel compositions for the delivery of pilocarpine or a pharmaceutically acceptable salt thereof across the oral mucosa, preferably across the buccal mucosa. In particular, the buffer systems in the compositions of the present invention contain an amount of a strong base that is less than the ... 02/09/06 - 20060029664 - Dosage form containing carbetapentane and another drug A pharmaceutical dosage form which comprises carbetapentane and/or a pharmaceutically acceptable salt thereof and an additional drug. The dosage form provides a plasma concentration within the therapeutic range of the additional drug over a period which is coextensive with at least about 70% of the period over which the dosage ... 02/09/06 - 20060029663 - Solid formulation The present invention provides a solid formulation comprising a xanthine derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, which possesses excellent pharmaceutical properties, for example, in hardness, disintegration property, dissolution property, stability or the like. ... 02/02/06 - 20060024364 - Directly compressible formulations of azithromycin The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed ... 02/02/06 - 20060024363 - Directly compressible formulations of azithromycin The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed ... 02/02/06 - 20060024362 - Composition comprising a benzimidazole and process for its manufacture The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention. ... 02/02/06 - 20060024361 - Disintegrant assisted controlled release technology A disintegrant assisted controlled release device is disclosed. The device is a combination of a swelling disintegrant or super-disintegrant and water insoluble polymer or water soluble polymer, or both, and one or more water soluble or water insoluble active pharmaceutical ingredient(s). The said device is stabilized by a humectant or ... 01/26/06 - 20060018961 - Compression formed preparation and method for manufacturing same A compression formed preparation that rapidly disintegrates in the mouth or in an aqueous solvent, which imparts an excellent feeling during administration, and maintains a suitable hardness required for handling such as distribution and the like, and a method for manufacturing the compression formed preparation. The present invention provides a ... 01/26/06 - 20060018960 - Galenic formulations of organic compounds The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form. ... 01/26/06 - 20060018959 - Solid drug for oral use prodrug, pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein said pharmaceutical is prepared to have 85% dissolution time of not more than 60 minutes in a dissolution test according to method 2 (paddle method) of Japanese pharmacopoeia in a condition using water. ... 01/19/06 - 20060013872 - Pharmaceutical compositions comprising ibuprofen and domperidone A stable pharmaceutical composition comprising a mixture of (i) an ibuprofen medicament; (ii) a domperidone medicamement; and (iii) a carrier material characterized in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent. ... 01/19/06 - 20060013871 - Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution This invention provides methods for enhancing the dissolution rate of Ibuprofen. More particularly, the invention provides a process for enhancing the solubility of Ibuprofen by intimately coating Ibuprofen particles with a Poloxamer. The invention also provides for a composition comprising a solid dosage form of Ibuprofen, wherein the surfaces of ... 01/19/06 - 20060013870 - Pharmaceutical compositions of hops resins The present invention is drawn to a pharmaceutical composition comprising a dry free flowing powder. The powder can include various combinations of alpha acid, iso-alpha acids, and beta acids. The composition can further include a silica salt absorbent and/or an anti-oxidant. These compositions are preferably prepared by mixing hops extract ... 01/19/06 - 20060013869 - Electrospun amorphous pharmaceutical compositions The present invention is directed to use of electrospinning, i.e. the process of making polymer nanofibers from either a solution or melt under electrical forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers. ... 01/12/06 - 20060008522 - Pharmaceutical excipient having improved compressibility A method of preparing an excipient composition includes forming an aqueous slurry containing a mixture of microcrystalline cellulose in the form of a wet cake and a surfactant, said surfactant being present in an amount from about 0.1% to about 0.5% by weight of the wet-cake microcrystalline cellulose; and drying ... 01/12/06 - 20060008521 - Tablet excipient This invention relates to a composition comprising physically modified, partially pregelatinized starch, which is useful as a multi-functional excipient for solid dosage forms, a method of making such composition, and solid dosage forms prepared using the composition. Such composition is characterized by a predominance of particles having both birefringent and ... 01/05/06 - 20060003000 - Adhesively bonded dosage form A solid pharmaceutical dosage form having a plurality of adhesively-joined subunits and also having one or more of the following: A. (i) a first inert tablet subunit and (ii) a second active subunit; B. (i) a first tablet subunit with a pharmacologically inactive layer in which said layer has a ... 01/05/06 - 20060002999 - Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following ... 12/29/05 - 20050287209 - Directly compressible formulations of azithromycin The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed ... 12/29/05 - 20050287208 - Cross-linked powered/microfibrillated cellulose ii A new cellulose excipient, UICEL-XL, suitable for use as a binder, filler, and/or disintegrant in the development of solid dosage forms is described. UICEL-XL incorporates a cross-linking agent which provides the excipient with a high degree of crystallinity, high water affinity, and a high specific surface area, thus providing good ... 12/29/05 - 20050287207 - Solid preparation The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which is useful as a therapeutic drug for diabetes and the like, and which is superior in preparation characteristics such as content uniformity and dissolution property of the insulin sensitizer and the ... 12/15/05 - 20050276847 - Oral delivery system The present invention relates generally to formulations comprising paracetamol. More particularly, the present invention provides a swallow formulation comprising paracetamol which facilitates the rapid delivery of paracetamol into the circulatory system following oral administration. The present invention further relates to methods for inducing efficient pain relief including an analgesic effect ... 12/15/05 - 20050276846 - Solid dose delivery vehicle and methods of making same The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing ... 12/15/05 - 20050276845 - Solid dose delivery vehicle and methods of making same The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing ... 12/15/05 - 20050276844 - Bioavailable compositions of metaxalone and processes for producing the same Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) ... 12/08/05 - 20050271721 - Carvedilol-hydrophilic solutions The present invention is concerned with pharmaceutically acceptable compositions comprising carvedilol or a pharmaceutically acceptable salt thereof distributed as a molecular dispersion in a concentration above 5% (wt./wt.), as well as pharmaceutical administration forms comprising such compositions and their use for the treatment and/or prophylaxis of illnesses such as hypertension, ... 12/08/05 - 20050271720 - Pharmaceutical composition containing irbesartan This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which ... 12/08/05 - 20050271719 - Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight The invention disclosed herein relates to a pharmaceutical composition comprising a carrier and an active ingredient, wherein the carrier is at least one fish gelatin predetermined on the basis of the molecular weight profile of the gelatin. In some embodiments, particularly when the concentration of carrier comprises a relatively lower ... 12/01/05 - 20050266075 - Omeprazole dosage form The present relates to a stable pharmaceutical composition comprising as an active component thereof one or more known 2-[(2-pyridyl)]-methylsulphinyl]benzimidazole derivatives ... 12/01/05 - 20050266074 - Ingestible device platform for the colon An ingestible pill platform for colon imaging is provided, designed to recognize its entry to the colon and expand in the colon, for improved imaging of the colon walls. On approaching the external anal sphincter muscle, the ingestible pill may contract or deform, for elimination. Colon recognition may be based ... 12/01/05 - 20050266073 - Fast disintegrating granules containing bromhexin/bromhexinhydrochloride, process for their preparation, and their use in veterinary medicine The invention relates to rapidly dissolving granules obtainable by preparing an aqueous granulating liquid containing at least one binder; spraying the granulating liquid obtained in step (a) in a fluidized bed by the counter-flow method at a constant air supply temperature on to a carrier containing at least one carbohydrate, ... 12/01/05 - 20050266072 - Pharmaceutical compositions Pharmaceutical compositions containing a therapeutically active agent, a diffusion barrier coating and coating comprising a hydrophobic material. ... 11/24/05 - 20050260262 - Dosage forms of bisphosphonates Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower ... 11/10/05 - 20050249808 - Nsaids compositions containing tartaric acid The invention is a composition and method for treating acute pain using a composition containing one or more NSAIDs. The preferred composition includes ibuprofen, sodium bicarbonate, Gelucire, and tartaric acid ... 11/10/05 - 20050249807 - Pharmaceutical formulations The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug ... 11/10/05 - 20050249806 - Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid related disorders and treating inflammatory disorders, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug. ... 11/10/05 - 20050249805 - compositions and methods for treating hepatitis c virus (hcv) infection Provided are compositions and methods for protecting a compound comprising a haloalkylamide moiety from metabolic transformation by hydrolases. In one aspect, the disclosure is directed to increasing the bioavailability and tissue delivery of a anti-HCV compound comprising a haloalkylamide moiety by protecting the compound from inactivation by carboxylesterases. Specific approaches ... 11/10/05 - 20050249804 - Stabilized short-course chemotherapy (scc) anti-tuberculosis drug compositions A stabilized oral powder or granule mixture made from at least two different anti-microbial tuberculosis drugs (e.g., rifampacin, isoniazid, ethambutol, pyrazinamide), for a short-course therapy; the powder can be consumed by mixing in a glass of water or juice and assures that each of the various drugs is in fact ... 11/03/05 - 20050244493 - Rapidly disintegrating tablets comprising calcium carbonate Solid-form, orally-administered, rapidly disintegrating pharmaceutical products and oral care tablets are provided. The tablet comprises: a calcium carbonate; a super disintegrant; and a sugar alcohol. When immersed in water the tablet has a friability of less than about 2% and disintegrates in less than about 60 seconds. ... 11/03/05 - 20050244492 - Rapidly disintegrating tablets comprising titanium dioxide An orally-administered, rapidly disintegrating tablet is provided. The tablet comprises: a titanium dioxide; a super disintegrant; and a sugar alcohol. When immersed in water the tablet has a friability of less than about 2% and disintegrates in less than about 60 seconds. ... 11/03/05 - 20050244491 - Fast disintegrating meloxicam tablet The present invention relates to a fast disintegrating tablet comprising meloxicam or a pharmaceutically acceptable salt thereof, starch or various starches, glidant and at least one additional excipient. ... 10/27/05 - 20050238712 - Quickly disintegrating solid preparations Quickly disintegrating solid preparations which contain: a) an active ingredient; b) D-mannitol having an average particle size of 30 μm to 300 μm; c) a disintegrating agent; and d) celluloses. ... 10/27/05 - 20050238711 - Filled depression tablets and method for their production ii A tablet having a base tablet having a depression and a solid filling the depression, wherein the solid filling the depression is secured in the depression by a fixative, and wherein a space is formed between the depression surface and the solid that is not filled with the fixative. ... 10/27/05 - 20050238710 - Vitamin replacement as a hangover ameliorative Metabolizing alcohol requires B vitamins and other nutrients in the liver. A person who drinks a large quantity of alcohol depletes those vitamins and nutrients. With lowered vitamins and nutrients a person feels uncomfortable following drinking, commonly called a hangover. A hangover ameliorative has four pills of vitamins and nutrients ... 10/27/05 - 20050238709 - Methods and devices for providing prolonged drug therapy Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose ... 10/20/05 - 20050232991 - Storage stable thyroxine active drug formulations and methods for their production This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, ... 10/20/05 - 20050232990 - Donepezil formulations Donepezil formulations, including amorphous donepezil or pharmaceutically acceptable salts thereof; sustained-release formulations; and donepezil sprinkle formulations are disclosed. ... 10/20/05 - 20050232989 - Process for preparing oral calcium compositions A process for the preparation of an orally administrable calcium composition comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 μm, having a crystalline structure and having a surface area of 0.1 to 1.2 m2/g; (ii) ... 10/20/05 - 20050232988 - Orally disintegrating tablets and methods of manufacture A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least ... 10/20/05 - 20050232987 - Dosage form containing a morphine derivative and another drug A pharmaceutical dosage form which comprises a first drug which comprises at least one morphine derivative with antitussive activity and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with ... 10/20/05 - 20050232986 - Dosage form containing promethazine and another drug A pharmaceutical dosage form which comprises promethazine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period ... 10/20/05 - 20050232985 - Ciprofloxacin hcl This invention relates to Ciprofloxacin Hydrochloride-containing composition, useful for the treatment of diseases. In particular, it relates to pharmaceutical composition comprising the following essential components: i) Ciprofloxacin Hydrochloride; ii) Magnesium stearate; iii) Starch; and iv) Carboxymethylstach Sodium. ... 10/13/05 - 20050226925 - Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic ... 10/13/05 - 20050226924 - Composition comprising itraconazole for oral administration The present invention relates to a composition comprising itraconazole for oral administration, more precisely, a composition for oral administration containing 1 part by weight itraconazole, 0.1-0.5 part by weight citric acid and 0.1-0.5 part by weight hydroxypropylmethylcellulose. The composition of the present invention has the advantages of mitigating discomfort of ... 10/13/05 - 20050226923 - Venlafaxine compositions in the form of microtablets A pharmaceutical composition comprising microtablets, wherein said microtablets comprise from about 0.1 weight percent to about 99.9 weight percent of venlafaxine, about 0.1 weight percent to about 20 weight percent of a lubricant, and optionally one or more excipients, wherein said weight percents are based on the total weight of ... 10/06/05 - 20050220871 - Taste masking granules Pellets of granulated particles comprising at least one pharmaceutically active compound, which pellets are characterised in that a bad taste of a pharmaceutically active compound when taken by patients is reduced or eliminated, said pellets comprise a pharmaceutically active compound and further comprise an organic carboxylic acid and/or a surfactant ... 10/06/05 - 20050220870 - Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to a gastrointestinal disorder or disease in a subject in need thereof. In one aspect, the present invention ... 10/06/05 - 20050220869 - Particulate compositions The present invention is a method for forming a composition in solid particulate form from a mixture of constituents, at least one of which is a liquid, the method comprising forming said composition from a mixture of constituents comprising a lipophilic liquid, a hydrophilic solid dispersant, and a solid particulating ... 09/29/05 - 20050214367 - Processes for making coated phytochemicals and tocopherols and products formed therefrom Methods and processes are provided herein for coating tocopherol succinate and phytoestrogen, e.g., an isoflavone. The methods include dispersing tocopherol succinate or phytoestrogen (e.g., an isoflavone) in a solvent and a coating composition, and then drying the composition. Coated tocopherol succinate and phytoestrogens (e.g., isoflavones) are also provided. ... 09/29/05 - 20050214366 - Anti-first-pass effect compounds Compositions, methods, etc. for addressing the first-pass effect. ... 09/29/05 - 20050214365 - [instant dissolving tablet composition for loratidine and desloratidine] Disclosed here is a tablet formulation of loratidine and desloratidine, non-sedating antihistaminic agents, that allows fast dissolution of tablets in the mouth allowing administration of these drugs without the aid of water. The formulation has pleasing taste and texture. ... 09/22/05 - 20050208130 - Tablet formulations comprising valsartan The invention relates to solid oral dosage forms comprising pharmacologically effective amounts of valsartan or a pharmaceutically acceptable salt thereof or hydrate thereof. The compositions are at least 1.2 times more bioavailable than conventional valsartan capsule. ... 09/22/05 - 20050208129 - Prolonged release bioadhesive therapeutic systems The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% ... 09/22/05 - 20050208128 - Immediate release tablet A new oral IR formulation in solid form for a low molecular weight thrombin inhibitor having pH dependant dissolution, characterized in that the formulation comprises a filler or a combination of fillers having disintegrant properties in an amount higher than 35% w/w of the formulation. ... 09/22/05 - 20050208127 - Rapidly disintegrating tablet and process for producing the same This invention provides small-sized, intrabuccally rapidly disintegrating tablets comprising D-mannitol having an average particle diameter of 31 μm to 80 μm, an active ingredient, a disintegrant and stearic acid or a metallic stearate of 0.01% by weight to 0.5% by weight, which have sufficient hardness, do not disintegrate during usual ... 09/22/05 - 20050208126 - Chemical ifg-i composition for the treatment and prevention of neurodgenerative diseases The invention relates to novel, sustained-release IGF-I therapeutic compositions, a preparation and production method thereof and the use of same in the production of medicaments for the treatment and prevention of neurodegenerative diseases such as, among others, Alzheimer's disease or cerebellar ataxia. The inventive compositions take the form of microspheres ... 09/15/05 - 20050202085 - Unit dose of material in system and method The invention provides a unit dose of an orally consumable material, having a predetermined pharmaceutically effective amount of at least one nonprescription discomfort reliever and a predetermined nutritionally effective amount of at least one nutritional supplement. Each unit dose may be in a container having indications of the amount discomfort ... 09/15/05 - 20050202084 - Pharmaceutical compositions A pharmaceutical composition in the form of a chewable tablet for the suppression of gastric reflux comprising an alginic acid or salt thereof, a water-soluble carbonate radical precursor, a calcium salt, a first bulk sweetener, and a binding agent. The calcium salt and either or both of the bulk sweetener ... 09/15/05 - 20050202083 - Storage stable tablets of fosinopril sodium The technical field of the present invention relates to the selection of lubricants to provide a storage stable tablet of fosinopril, alone or in combination with a diuretic, as well as processes of preparation of the stable tablets. In particular, the lubricants are a combination of colloidal silicon dioxide and ... 09/15/05 - 20050202082 - Press-coated molded article undergoing quick disintegration A press-coated fast-dissolving/disintegrating molded product of the present invention is characterized in that the molded product comprises an inner core that contains ingredients rich in dissolubility or/and disintegrability and whose disintegration time is 1 minute or less and an outer layer that contains ingredients rich in moldability on the outside ... 09/08/05 - 20050196440 - Mucoadhesive drug delivery devices and methods of making and using thereof The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug ... 09/08/05 - 20050196439 - Process for co-spray drying agents with dry silicified mcc A process for preparing agglomerated particles comprising a) providing an active agent in a form suitable for spray drying; and b) combining the active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles. ... 09/08/05 - 20050196438 - Fast dissolving tablet and method of preparing the same A fast dissolving tablet. The fast dissolving tablet comprises a pharmaceutically active ingredient, a starch, a hydrophilic polymer, a surfactant, and excipients. A method of preparing the fast dissolving tablet is also disclosed. ... 09/01/05 - 20050191350 - Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof Provided are formulations of a stable commercial paroxetine tablet comprising paroxetine hydrochloride anhydrous, povidone, copovidone or HPMC as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method. ... 09/01/05 - 20050191349 - Galantamine formulations Galantamine formulations, including sustained-release and fast dissolve formulations, are described. ... 09/01/05 - 20050191348 - Use of propargylamine as neuroprotective agent Propargylamine and pharmaceutically acceptable salts thereof are useful for treating a disease, disorder or condition selected from the group consisting of: (i) a neurodegenerative disease, (ii) a dementia; (iii) an affective or mood disorder; (iv) drug use and dependence; (v) a memory loss disorder; (vi) an acute neurological traumatic disorder ... 08/25/05 - 20050186274 - Multilayer tablet A multilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix, a second layer formulated for instant release of the angiotensin converting enzyme inhibitor ramipril and optionally a diuretic from a disintegrating tablet matrix, and, optionally, a third ... 08/25/05 - 20050186273 - Controlled release dosage form including a banded engine The present invention includes a dosage form configured to provide the controlled release of an active agent formulation. A dosage form according to the present invention includes a reservoir containing an active agent formulation and an engine positioned at least partially within the reservoir. In order to reduce the possibility ... 08/25/05 - 20050186272 - Pharmaceutical composition for oral application and method for preparing thereof The present invention relates to a pharmaceutical composition for oral application comprising: i) an anthelmintic agent; ii) a first excipient having a porous structure with an inner surface of about 500 to 1500 m2/g and a surface area according to BET of up to about 5000 m2/g; as well as ... 08/25/05 - 20050186271 - Process for dispersing a fluid in a mass of solid particles A fluid is dispersed in a mass of solid particles in a process wherein a) a gas is contacted with a fluid composition comprising i) from 0.001 to 30 weight percent of a surfactant having a weight average molecular weight of up to 30000 and ii) from 99.999 to 70 ... 08/25/05 - 20050186270 - Stable tablets comprising simvastatin A tablet comprising simvastatin and excipients, wherein the content of lactose, if any, is less than 75 percent of the total excipients by weight, and wherein the content of cellulose is more than 20 percent of the total excipients by weight. ... 08/18/05 - 20050181045 - Vaginally administrable progesterone-containing tablets and method for preparing same The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the ... 08/18/05 - 20050181044 - Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract The present invention relates to compositions of and methods for producing timed or retarded release formulations that contain green coffee extract, and optionally vinpocetine, L-camitine, of amylase inhibitor, niacin, Vitamin B3 (niacinamide), vitamin B6 (pyridoxine hydrocholoride), vitamin B12 (cyanocobaolamin), vitamin B5 (pantothenic acid), inositol, phosphorus, iodine, and chromium and/or their ... 08/18/05 - 20050181043 - Alendronate salt tablet compositions A tablet composition comprising an alendronate salt and optionally one or more excipients, wherein the cumulative total of the alendronate salt particles in the composition have a particle size distribution as follows: (a) about 19% to about 25% of the particles have a particle size of 250 microns as determined ... 08/18/05 - 20050181042 - Composition for oral or rectal administration A solid pharmaceutical or food supplement tablet or suppository composition has a melting point of 25° C. or higher and comprises a continuous lipid component comprising one or more polar lipids, one or more non-polar lipids, optionally one or several of water and mono- to trivalent alcohol in an amount ... 08/11/05 - 20050175690 - Novel drug compositions and dosage forms The present invention is directed to novel drug compositions and dosage forms comprising said drug compositions. The drug compositions of the present invention comprise a pharmaceutical agent and a solubilizing agent. The drug compositions of the present invention are particularly advantageous for use with low solubility and/or low dissolution rate ... 08/11/05 - 20050175689 - Coated fine particles containing drug for intrabuccally fast disintegrating tablet The present invention makes it possible to provide drug-containing coated microparticles for quick-disintegrating oral tablets wherein microparticles containing a drug with an unpleasant taste are coated with a film composed of (1) a pH-independent water-insoluble polymer accounting for 60% or more but less than 80% of the film and (2) ... 08/11/05 - 20050175688 - Method of treating pain in a subject by the administration of aminobenzoate potassium Provided is a novel method of treating chronic pain symptoms associated with a fibrotic condition in a subject in need of such relief. Particularly provided is a method for treatment of chronic pain associated with fibrosis and resulting adhesions and, more particularly, a method for treating chronic pelvic pain in ... 08/11/05 - 20050175687 - Pharmaceutical formulations The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units ... 08/04/05 - 20050169989 - Generally linear effervescent oral fentanyl dosage form and methods of administering Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa. ... 08/04/05 - 20050169988 - High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability Orally ingestible bioactive agents are disclosed which contain a triglyceride matrix and one or more polyphenols that improve the bioavailability of the bioactive agent. In particular non-limiting examples, the bioactive agent is a ubiquinone (such as Coenzyme Q), the triglyceride matrix is a soybean oil matrix, and the composition further ... 08/04/05 - 20050169987 - Compacted menthol The invention provides menthol mouldings, a process for producing menthol mouldings and the use thereof. ... 08/04/05 - 20050169986 - Fast disintegrating tablets A fast disintegrating tablet comprising an active ingredient and one or more disintegrants characterised in that the tablet comprises agglomerates having an agglomerated particle size of at least 50 μm, said agglomerates comprising at least 10% by weight of a superdisintegrant selected from croscarmellose cellulose, crospovidone and sodium starch glycollate ... 07/28/05 - 20050163837 - Rosiglitazone formulations Rosiglitazone is a drug used to treat type 2 diabetes. Methods for the formation of amorphous rosiglitazone and formulations comprising the amorphous rosiglitazone are described. Other formulations include pulsed-release formulations and formulations for retention in the stomach and upper gastrointestinal tract. Controlled-release dosage form include those wherein the maximum plasma ... 07/28/05 - 20050163836 - Process for the preparation of tablets from pharmaceutically active substances having unfavourable tabletting properties with a granulating liquid comprising microcrystalline cellulose The invention refers to a process for the preparation of tablets that can be well compressed and have good mechanical strength from pharmaceutically active ingredient(s) having unfavourable tabletting properties. In the process of the invention a granulating liquid is used which is a suspension of 5-30% of microcrystalline cellulose—90% of ... 07/28/05 - 20050163835 - Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative A pharmaceutical composition comprising 4-(3′-chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The water-soluble cellulose ether or ester of a water-soluble cellulose ether present in the composition inhibits the rate of precipitation of the Agent from ... 07/21/05 - 20050158379 - Minimization of drug oxidation in drug irradiated excipients formulations This invention relates to compositions and methods for preventing oxidation of beneficial agents. ... 07/21/05 - 20050158378 - Method for preparing solid dosage form of desmopressin The present invention relates to a novel method for the preparation of a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, comprising providing a desmopressin containing granulate suitable for compression to a pharmaceutically acceptable tablet, as well as to solid dosage forms, preferably tablets, obtainable by said ... 07/14/05 - 20050152974 - Atomoxetine formulations The invention provides novel dosage forms of atomoxetine and its salts, particularly atomoxetine hydrochloride including wax dosage forms, press-coat dosage forms, and sprinkle dosage forms, and other novel dosage forms. The invention also provides sustained-release and pulsed-release dosage forms of atomoxetine and its salts. Methods of making novel atomoxetine dosage ... 07/14/05 - 20050152973 - Disintegrant The present invention relates to a disintegrant comprising a substance which is solid at room temperature and has a water solubility of 30 wt. % or more, a saturated aqueous solution of the substance having a viscosity of 50 mpa.s. ... 07/14/05 - 20050152972 - Soft chewable anesthetic lozenges A soft, chewable lozenge for relief of mouth pain contains, by weight, 10-60% hydrogentated starch hydrolysate, 3-60% hydrogenated mono- and di-saccharides, 1-20% hydrogenated vegetable oil, 0.5-27% gelatin, 0.25-7.5% anesthetic and 1-25% water. A method for treating mouth and throat pain by administering to a patient in need a soft, chewable, ... 07/07/05 - 20050147675 - Composition for the treatment and prevention of endothelial dysfunction A composition for the treatment and prevention of endothelial dysfunction comprising a therapeutically effective amount of anti-inflammatory agents comprising; NSAIDs, an amino sugar and a zinc compound combined with dietary supplements and a method for the treatment and prevention of endothelial dysfunction in mammals. ... 07/07/05 - 20050147674 - Crystalline composition containing escitalopram Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed. ... 07/07/05 - 20050147673 - Directly compressible sustained release formulation containing microcrystalline cellulose The present invention provides an improved process for the preparation of a agglomerated solid dosage form, comprising: (1) preparing an aqueous slurry of (a) microcrystalline cellulose; (b) a microcrystalline cellulose compressibility augmenting agent which (i) physically restricts the proximity of the interface between adjacent cellulose surfaces; (ii) inhibits interactions between ... 07/07/05 - 20050147672 - Tablets quickly disintegrating in mouth Tablets quickly disintegrating in the mouth which comprise a bitter drug ingredient and a bitterness-reducing ingredient composed of an essential oil, a high sweetness-sweetener and/or an acidic phospholipid or its lyso-derivative. When taken even without water, these tablets exhibit little bitterness. Thus, a bitter drug ingredient can be formulated without ... 07/07/05 - 20050147671 - Pharmaceutical compositions based on diclofenac New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain ... 07/07/05 - 20050147670 - Oral disintegrating dosage forms The invention is directed to pharmaceutical dosage forms having immediate release via rapid oral disintegration, specifically, orally disintegrating tablets containing levodopa and carbidopa. The invention further provides formulations containing relatively increased amounts of carbidopa than previously available, including, for example, formulations containing carbidopa-levodopa ratios of about 1:1 to about 1:3. ... 07/07/05 - 20050147669 - Rapid dissolution formulation of a calcium receptor-active compound The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a ... 07/07/05 - 20050147668 - Quick release pharmaceutical compositions of drug substances The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of an active substance (a drug substance) to obtain a relatively fast or quick onset of the therapeutic and/or prophylactic effect The drug substances contained in a modified release ... 07/07/05 - 20050147667 - Method of ensuring patient identification of prescribed drug and quantity for prescribed purpose and improved self-identifying drug appearance A technique for assuring patient use of the correct drug pill for a prescribed treatment of a particular body organ or part, involving shaping the pill to have an appearance resembling such body organ—in particular, appropriate prophylactic-dose aspirin pills of heart-shape, as well as other drug pills for treating other ... 07/07/05 - 20050147666 - Tablets quickly disintegrating in oral cavity According to the present invention, provided are an intraorally rapidly disintegrable tablet which comprises D-mannitol and a disintegrator in addition to fine granules prepared by granulating a mixture of a water-soluble pharmacologically active ingredient and an adsorbent; a process for producing an intraorally rapidly disintegrable tablet which comprises mixing D-mannitol ... 06/30/05 - 20050142196 - Stable pharmaceutical compositions containing an ace inhibitor A stable pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutical acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. ... 06/30/05 - 20050142195 - Stable pharmaceutical compositions without a stabilizer Stabilized controlled release pharmaceutical preparations are disclosed in which active ingredient degradation is prevented without the use of a stabilizer. The active ingredient is sealed away from excipients that can adversely affect stability by sealing the excipients rather than the active ingredient. The preparations are substantially unaffected by exposure to ... 06/30/05 - 20050142194 - Composition comprising cs The present invention concerns new chondroitin sulfate compositions with a twofold therapeutic action. The new compositions of the invention are characterised by a high patient compliance, being extremely useful for prolonged therapy. To achieve these aims, the new compositions contain primary and secondary structuring agents, as well as defined amounts ... 06/30/05 - 20050142193 - Galantamine formulations Galantamine formulations substantially free of microcrystalline cellulose, lactose, and/or starch are described. ... 06/30/05 - 20050142192 - Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives Solid, pharmaceutical dosage forms of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives thereof are disclosed. In addition, methods of use are disclosed for the treatment, inter alia, of cerebral vascular disorders, anxiety disorders; mood disorders; schizophrenia; schizophreniform disorder; schizoaffective disorder; cognitive impairment; chronic neurodegenerative disorders; inflammatory diseases; fibromyalgia; complications from herpes zoster; ... 06/30/05 - 20050142191 - Pharmaceutical formulations of amyloid inhibiting compounds Therapeutic formulations and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Therapeutic formulations and methods for preventing or treating amyloidosis and/or amyloid-related disease are also described. ... 06/30/05 - 20050142190 - Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same The invention provides a stable and easy to formulate amorphous solid, suitable for the preparation of solid pharmaceutical compositions comprising a mixture of an amorphous active pharmaceutical ingredient and at least one pharmaceutically acceptable inactive ingredient. ... 06/23/05 - 20050136106 - Therapeutic placebo enhancement of commonly used medications There is provided a method and associated kit for reducing the normal dosage of a pharmaceutical given to a patient for the treatment of a disorder without substantially reducing its effectiveness. During a first predetermined time period, a substantially full dosage of the pharmaceutical is administered to the patient, preferably ... 06/23/05 - 20050136105 - Consumer customized dosage forms Customizable dosage forms are provided. The flavor, color, sweetness, or texture of the dosage forms may be customized directly by the consumer. ... 06/16/05 - 20050129758 - Dietary fiber delivery system A delivery system and method for delivering soluble dietary fibers in a chewable tablet form which is palatable and demonstrates a high degree of consumer acceptability. ... 06/16/05 - 20050129757 - Process for producing solid dosage forms A process for producing solid dosage forms by mixing at least one polymer binder, at least one active ingredient and, where appropriate, conventional additives to form a plastic mixture, and shaping, wherein a physiologically tolerated, water-swellable graft copolymer or a mixture of graft copolymers is employed as polymeric binder. ... 06/16/05 - 20050129756 - Uv-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient The semisolid or liquid pharmaceutical preparation for transdermal administration contains at least one UV-light sensitive pharmaceutically active ingredient and at least one UV-absorbing substance, which is present in an amount that does not have pharmacological activity and in dissolved or dispersed form. This semisolid of liquid pharmaceutical preparation is preferably ... 06/09/05 - 20050123609 - Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration New pharmaceutical compositions in unit dosage form are disclosed for both intraoral and oral administration to a patient, said unit dosage form configured to be placed intraorally of said patient, which comprises: (a) as a first portion, at least one discrete molded triturate tablet comprising a therapeutically effective amount of ... 06/09/05 - 20050123608 - Preparation of powder agglomerate The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates ... 06/09/05 - 20050123607 - Pharmaceutical formulation of valaciclovir The invention relates to a pharmaceutical formulation of valaciclovir or a pharmaceutically acceptable salt thereof and a process of preparing such formulation. ... 06/09/05 - 20050123606 - Compositions of quaternary ammonium compounds containing bioavailability enhancers An oral pharmaceutical dosage form with enhanced gastrointestinal permeability, comprising a therapeutic quaternary ammonium compound together with an organic acid. ... 06/09/05 - 20050123605 - Anti-angiogenic compositions and methods of use The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions. ... 06/09/05 - 20050123604 - Pharmaceutical compositions A method of treating a cyclooxygenase-2 dependent disorder or condition comprising administering 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid in an amount effective to treat such a disorder or condition for about 24 hours, comprising administering orally once a day to a human in need of such treatment one or more immediate release pharmaceutical compositions ... 06/02/05 - 20050118260 - Method and apparatus for making a tablet product There is provided a method of forming a tablet product. The method comprises closing off a perforation in a perforated plate; directing powder into said closed-off perforation by the sweeping action of a first director blade spaced from said perforated plate; compacting the powder to form a tablet; and transferring ... 06/02/05 - 20050118259 - Formulations of quinapril and related ace nhibitors Stable formulations of ACE-inhibitors compounds such as quinapril can be produced with the use of excipients comprising a basic compound, preferably an alkali-oralkaline earth metal carbonate, and an insoluble alkaline-earth metal carbonate, and an insoluble alkaline-earth metal hydrogen phosphate. Tablets of such formulations have good storage stability, dissolution characteristics, and ... 06/02/05 - 20050118258 - Pharmaceutical composition comprising skim milk powder The present invention relates to a pharmaceutical composition comprising an unpleasant-tasting therapeutic agent and skim milk powder. The composition of the present invention may further comprise a conventional pharmaceutical excipient. A further aspect of the present invention is a method of making a pharmaceutical composition comprising the step of dry ... 06/02/05 - 20050118257 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological ... ### FreshPatents.com Support |